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 INTRODUCTION 
  
1 PARKINSON’ S DISEASE 
1.1 Brief history of Parkinson’s Disease 
 
Parkinson’s Disease (PD) was originally observed by James Parkinson in 
1817. In his monograph ”Essay on the Shaking Palsy” the British physician 
described the core clinical features of the disease then named paralysis 
agitans: “ Involuntary tremolous motion, with lessened muscular power, in parts 
not in action and even when supported; with a propensity to bend the trunk 
forewords and to pass from a walking to a running pace: the senses and the 
intellect being ininjured”. 
In the 1950s large efforts were spent to characterize biochemically this 
pathology, mostly by the Nobel Prize 2000 Arvid Carlsson. He 
demonstrated that Levodopa reverses the parkinsonian state induced by 
Reserpine in rabbits (1957), and that Dopamine (DA) is present in the 
brain (1958). Finally he discovered that PD patients showed a massive loss 
of DA (1960) which can be clinically reverted by the employment of 
Levodopa (1968). Furthermore, typical neuropathological hallmarks were 
described as the loss of dopaminergic neurons in the Substantia Nigra and 
the presence of intraneuronal inclusions called Lewy Bodies (LBs) in the 
surviving ones. However, despite this early description, the etiology of PD 
is still unclear and the neurodegenerative process is irreversible. 
 
1.2 Clinical characteristics of PD 
 
Nowadays PD is the second most common progressive neurodegenerative 
disorder after Alzheimer’s Disease (AD). It affects 1-2 % of all individuals 
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above the age of 65 years old, increasing to 4-5% by the age of 85. Old age 
is the greatest risk factor of PD, indeed the onset is extremely rare before 
age 40. Men are slightly more affected than woman. PD is a slowly 
progressive neurodegenerative disorder, which begins insidiously, 
gradually worsens in severity and usually affects one side of the body 
before spreading to involve the another side. PD is characterized by six 
cardinal features: tremor at rest, rigidity, bradikinesia, hypokinesia and 
akinesia, flexed posture of neck, trunk and limbs, loss of postural reflexes 
and freezing phenomenon. The early symptoms of PD are usually 
alleviated by the treatment with Levodopa and DA agonists. As PD 
advances from year to year, late symptoms such as flexed posture, loss of 
postural reflexes and freezing phenomenon, don’t respond to the 
Levodopa treatment. Furthermore, bradykinesia, that responded to 
Levodopa in the early stage of PD, worsens and does not respond to 
Levodopa any more. While motor symptoms dominate PD clinical 
features, many patients show other non-motor symptoms. These include 
fatigue, depression, anxiety, sleep disturbances, constipation, bladder and 
other autonomic disturbances (sexual and gastrointestinal), sensory 
complaints, decreased motivation, apathy and a decline in cognition that 
can progress to dementia. 
 
1.3 Neuropathological features of PD 
 
PD is due to the relatively selective loss (70-90%) of dopaminergic neurons 
in the Substantia Nigra pars compacta (SNc), which leads to a profound 
reduction in striatal dopamine (DA). The loss of dopaminergic neurons is 
asymmetric, slow and progressive as the disease itself. These neurons 
project into striatum caudate and putamen nuclei, that anatomically form 
basal ganglia (figure 1). Voluntary movements originate at motor cortex 
level: signals are sent through the encephalic trunk (mesencephalon, pons 
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and medulla) up to the spinal cord. These signalling pathways are 
controlled by different sub-cortical structures (thalamus, putamen and 
subthalamic nuclei) that modulate movements. Basal ganglia dopaminergic 
neurons depletions provoke movement control dysfunction and initiate 
the characteristic symptoms of PD [Dauer and Przedborski, 2003].  
With the progressive loss of dopaminergic neurons, there is a 
corresponding decrease of DA content in both the Substantia Nigra and the 
striatum. The loss of the nigrostriatal pathway can be detected during life 
using PET and SPECT scanning, showing a progressive reduction of 
fluoro-DOPA (FDOPA) and DA transporter ligand binding in the striatum. 
 
Fig 1: Schematic rapresentation of Substantia Nigra and pathways towards caudate and 
putamen nuclei in physiological (left) and PD conditions (right) (Dauer et al., 2003). 
 
The neuronal loss is accompanied by an increase in glial cells and loss of 
neuromelanin, pigment normally contained in dopaminergic neurons. LBs 
and dystrophic neuritis, also called Lewy Neurites (LNs), are present in 
some of the remaining dopaminergic neurons and are the typical 
pathological hallmark of PD. Classically, LBs are round eosinophilic 
inclusions composed of a halo of radiating fibrils and a less defined core 
(figure 2). Both LBs and LNs are composed by the accumulation of 
cytoplasmic aggregates containing a variety of proteins, of which α-
synuclein is a major component.  
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Interestingly, LBs are also present in other diseases that are associated 
with dementia (LBs dementia) [Bove at al., 2005, Gibb et al., 1987]. 
The role of LBs in PD neurodegenerative process, if they could be 
perpetrators or protective, remains a matter of fierce dabate. 
 
 
Fig 2: Immunohistochemical staining of Lewy Bodies found in dopaminergic neurons 
of PD patients in Substantia Nigra pars compacta. Unsoluble fibrous component of 
aggregates are detected with anti-α- synuclein antibody and anti-ubiquitin (Dauer et 
al., 2003). 
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1.4  Etiology of PD  
1.4.1 Sporadic Forms 
 
PD is a multifactorial disease caused by both genetic and environmental 
factors. The cause of sporadic PD is unknown, but the environmental 
hypothesis was dominant for much of the 20th century. The finding that 
people intoxicated with 1-methyl-4-phenyl-1,2,3,4-tetrahydropyrydine 
(MPTP) develop a syndrome nearly identical to PD (Langston et al., 1983) 
is a prototypic example of how an exogenous toxin can mimic the clinical 
and pathological features of PD. Human epidemiological studies have 
implicated residence in rural environment and related exposure to 
herbicide (i.e. Paraquat) and pesticides (i.e. Rotenone) with an elevated 
risk for PD. Instead, cigarette smoking and coffee drinking are inversely 
correlated to the risk for PD development (Hernan et al., 2002). 
 
1.4.2 Genetic forms 
 
In recent years, linkage analyses and positional cloning of an increasing 
number of genes that are linked to inherited forms of PD have provided 
new insights into PD pathogenesis. Although 90% of all PD cases are 
sporadic, 10 % of all cases are characterized by a positive familiar history. 
Therefore, in the last ten years great efforts has been spent to identify the 
PD genes. Up to now 13 monogenic PD forms have been described, 
(labelled from PARK 1 to PARK 13): in nine cases it was possible to 
identify the genes involved (Table 1). 
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 TYPE
PARK 1
PARK 2
PARK 3
PARK 4
PARK 5
PARK 6
PARK 7
PARK 8
PARK 9
PARK 10
PARK 11
PARK 12
PARK13
LOCUS
4q21-23
6p25.2-27
2p13
4p14-16.3
4p14
1p35-36
1p36
12p11.2-13.1
1p36
1p32
2q36-37
Xq23-25
2p13
GENE
α-synuclein
Parkin
Unknown
α-synuclein
UCH-L1
PINK-1
DJ-1
LRRK2
ATP13A2
Unknown
Unknown
Unknown
Omi-HtrA2
TRANSMISSION
AD
AR
AD
AD
AD
AR
AR
AD
AR
NP
AD
XR
AD?
LEWY BODIES
+
-
+
+
?
+
?
+
?
?
?
?
?
 
Table 1: Genetic loci and genes identified in PD. 
 
1.5 Pathogenesis of PD 
 
Whatever is the initial insult that provokes the dopaminergic 
neurodegeneration, studies of toxic PD models and of the biological 
function of the genes implicated in inherited forms of PD suggest two 
major hypotheses regarding the pathogenesis of the disease:  
1. misfolding and aggregation 
2. mitochondrial dysfunction and the consequent oxidative stress. 
These two hypotheses are here discussed. 
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1.5.1 Misfolding and aggregation of proteins 
 
The abnormal protein deposition in brain tissue is a feature of several age-
related neurodegenerative disorders. Although the compositions and 
locations are different from disease to disease, this common feature 
indicates that the deposition itself could be toxic. 
As anticipated, LBs, the tipical hallmark of surviving dopaminergic 
neurons, are cytoplasmic aggregates, mainly containing α-synuclein. This 
natively unfolded protein has a great propensity to aggregate both in vitro 
and in vivo, especially in the presence of several herbicide and pesticide. 
Moreover, two PD-linked mutants (Ala30Pro and Ala52Thr) show a great 
propensity to form protofibrils. 
Cells respond to misfolded proteins by inducing chaperone activities. 
When misfolded proteins cannot be properly refolded, they are targeted 
for proteosomal degradation by polyubiquitination. It is interesting to 
note that LBs are immunoreactive against Chaperone proteins (i.e. Hsp-
70), Ubiquitin, and components of the 26S of the proteosome system. 
Protein aggregates may interfere with intracellular trafficking in neurons 
or sequestrate proteins important for cell survival. This hypothesis 
considers LBs as perpetrators although till now there is no clear 
correlation between inclusion formation and neuronal cell death. 
Alternatively, LBs could be considered as protectors. The increasing 
demand of protein degradation, hypothesis proposes that LBs form late in 
the disease after cells have tried all their the consequent failure of the 
Ubiquitin Proteosome System (UPS) to process abnormal proteins, and the 
resulting accumulation of misfolded proteins, lead to the formation of 
aggregates that can be removed by autophagy. 
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In inherited PD cases, pathogenic mutations could be directly involved by 
inducing abnormal and toxic protein conformations (i.e. α-synuclein) or 
interfering with the processes that normally recognize misfolded proteins.  
Mutations in Parkin were first linked to autosomal recessive juvenile 
Parkinsonism (ARJP) and are the most frequent cause of autosomal 
recessive PD. Parkin is an E3 ubiquitin protein ligase that is upregulated 
under unfolded protein stress. 
Working in concert with the E1 activating enzyme and the E2 conjugating 
enzyme, Parkin can ubiquitinate specific substrates (such as Cycline E, α-
synuclein, Pael Receptor and Synphilin-1) thereby targeting them for 
proteasomal degradation. Considering that the majority of the patients 
with parkin mutation lacks LBs pathology, it has been suggested that 
parkin may promote LBs formation (Mizuno et al., 2001), mostly because 
in sporadic PD patients these inclusions are immunoreactive for some of 
parkin substrates. Even if parkin fails to directly ubiquitinate α-synuclein 
(Chung et al., 2001), it interacts with the α-synuclein interacting protein 
synphylin I, and through its interaction it may promote LBs formation. 
Alternatively, parkin-mediated neurodegeneration may proceed through a 
mechanism that is distinct from those that occur in the cases of PD with 
LBs.  
The linkage with PD of PARK5 gene also supports the notion that 
derangements in the UPS may contribute to DA neuronal death. PARK5 
encodes for UCH-L1, which hydrolyzes ubiquitin from polymeric chains 
and from ubiquitinated proteins producing monomeric units. UCH-L1 has 
also been found in the LBs of patients with sporadic PD. This finding 
provides an additional evidence for the involvement of aberrant 
ubiquitinilation and aggregates formation in the PD pathogenesis. 
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1.5.2 The oxidative stress hypothesis 
 
The hypothesis that oxidative stress plays a role in the pathogenesis of PD 
was fuelled by the discovery that MPTP blocks the mitochondrial electron 
transport chain by inhibiting complex I (Nicklas et al., 1987).  
MPTP is highly lipophilic, and it crosses the blood brain barrier within 
minutes (Markey et al., 1984). Once in the brain, MPTP is oxidized to 1-
methyl-4 phenyl-2,3-dihydropyridinium (MPDP+) by monoamine oxidase 
B (MAO B) in glia and serotonergic neurons and then is spontaneously 
oxidazed to MPP+. Due to its high affinity for the DA Transporter (DAT), 
it is selectively accumulated in dopaminergic neurons, where it causes 
toxicity and neuronal death through complex I inhibition (figure 3). 
Similar toxic effects are produced by the common herbicide 1,1’-dimethyl-
4,4’-5 bipyridinium (Paraquat) coupled with the amministration of the 
fungicide manganese ethylenepistithiocarbamate (Maneb). While 
Paraquat, which is structurally similar to MPTP, blocks the mitochondrial 
complex I, Maneb inhibits the mitochondrial complex III. Derangements in 
complex I cause α-synuclein aggregation, which further contributes to the 
demise of Dopaminergic neurons (Dawson and Dawson, 2003). 
Furhermore, genetic defects in the mitochondrial complex I could 
contribute to cell degeneration in PD through decreased ATP synthesis.  
Selective decrease in the activity of mitochondrial complex I has also been 
found in the Substantia Nigra of PD patients (Shapira et al., 1990). A 
consequence of the mitochondrial dysfunction is oxidative stress and 
viceversa. Ninety-five percent of the molecular oxygen is metabolized 
within the mitochondria by the electron-transport chain: thus 
mitochondria are highly exposed and damaged by oxidative stress and 
this leads to a more intense and perpetuating cycle in which reactive 
oxygen species (ROS) are generated. 
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3A                                                     3B 
 
 
 
 
 
 
 
 
 
 
            Fig 3: A) Schematic representation of the MPTP metabolism and B) of MPP+ 
intracellular pathway (Dauer at al., 2003).  
 
ROS cause functional alterations in proteins, lipids and DNA. Lipid 
damage leads to loss of membrane integrity and ions permeability, 
promoting excitotoxicity (Halliwell, 1992). Although ROS levels cannot be 
directly measured, the assessment of their reaction products and of the 
resulting damage in post mortem tissues is as an indirect index of their 
levels (Foley and Riederer, 2000).  
Many factors lead to oxidative stress in SNpc. The reduced content of the 
anti-oxidant glutathione in the SNpc of PD brains lowers the capability to 
clear H2O2. Moreover, the increased free iron level can promote OH∗ 
formation and DA oxidation into toxic dopamine-quinone species 
(Graham et al, 1978). The impairment of the complex I system may be 
central in PD pathogenesis of DA neurons since its defects and inhibitors 
cause dopaminergic cell death and induce the formation of filamentous 
inclusions containing α-synuclein. A complex interaction between 
mitochondrial dysfunction, oxidative stress and the propensity to form 
aggregates occur (figure 4). Complex I inhibitors causes a reduction in the 
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proteosomal activity (Shen et al., 2004) and conversely proteosomal 
inhibition can cause mitochondrial damage (Hoglinger et al., 2003). 
Further studies are needed to understand the biochemical pathways 
involved in dopaminegic neurons cell death, including the interaction 
between oxidative stress and aggregates formation through UPS 
impairment. 
 
Fig 4: Mechanism of neurodegeneration: linking oxidative stress and mitochondrial 
damage to UPS impairment and aggregates formation (Dauer et al., 2003). 
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2 DJ-1 IN PARKINSON’S DISEASE 
 
After the identification of the PARK-7 locus by van Dujin et al., Bonifati et 
al. have shown mutations in the DJ-1 gene in two PARK-7 linked families. 
The Dutch family displays a large homozygous deletions of exons 1-5 of 
the DJ-1 gene and an Italian kindred harbors a single missense mutation at 
an highly conserved position, Leu166Pro. 
Till now different mutations affecting DJ-1 (including missense, truncating 
and splice-site mutations and large deletions) have been linked to 
autosomal recessive PD. The homozygous deletions found in PARK-7 
patients represent a natural knock out, indicating that the loss of function 
is pathogenic. Several studies indicate that the mutant Leu166Pro is 
unstable and thus degraded through the UPS (Miller et al.,2003; Olzmann 
et al., 2004; Blackinton et al., 2005). It is worth noting that position 166 is 
localized in the penultimate C-terminal α-helix near the dimer interface 
and the mutation to proline is predicted to interrupt the helix (Tao et al., 
2003; Moore et al., 2003; Olzmann et al., 2004). The Leu166Pro mutant 
doesn’t dimerize but is rapidly degraded as monomer. Interestingly, other 
studies indicate that Leu166Pro tends to form multimeric aggregates 
(Baulac et al., 2004; Macedo et al., 2003; Olzmann et al., 2004). The 
Leu166Pro monomer has been recently shown to possess a different 
conformation from the wild type DJ-1 and the data computational analysis 
indicates that Leu166 is not located at the subunit surface involved in the 
dimerization. Thus the different conformation of Leu166Pro monomeric 
units might affect the protein-protein interaction repertory (Herrera et al., 
2007). 
The pathogenic role of other mutants remains to be established. 
Some of them might be simple polymorphisms that predispose to PD, as 
demonstrated for the Arg98Gln.  
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Although DJ-1 mutations account for only a small fraction of early onset 
PD (1-2%), they are the second most frequent cause of recessive forms of 
PD (Heidrich K et al., 2004), after PARK2-linked families.  
Clinically, DJ-1-dependent PD is characterized by early onset of 
parkinsonism (the average age is the early 30s), slow disease progression 
and good initial response to Levodopa. 
Psychiatric and behavioural disturbances (including severe anxiety and 
psychotic episodes) are reported in both original DJ-1 families (Abou-
Sleiman et al., 2004). Further analysis is necessary to investigate whether 
this aspect is more frequent in DJ-1 patients than in other PD forms. 
 
2.1 DJ-1 gene and protein distribution 
 
DJ-1 gene spans 24 kb and contains seven exons, the first two are non-
coding and subject to alternative splicing in mRNA. (Taira et al., 2001) It 
encodes a small 189-aminoacid protein that is ubiquitously expressed and 
widely distributed in brain and other tissues. It is conserved through 
different species (Bandopadhyay and Cookson, 2004) and determination 
of crystal structure of human DJ-1 has demonstrated that it exists in 
homodimeric form, essential to retain its biological function (Olzmann et 
al., 2004). In human brain, DJ-1 has a marked astrocytic expression 
(Bandopadhyay et al., 2004), while neuronal labelling is very weak. It 
never localizes at LBs or LNs (Bandopadhyay et al.,2005). On the contrary, 
in the murine brain DJ-1 presents both a neuronal and glial expression.  
Bader at al. found DJ-1 expression in murine neurons of different 
neurotransmitter phenotypes and in all glial types, such as astrocytes, 
microglia, and oligodendrocytes. The high DJ-1 expression is not confined 
to a single anatomical area, considering that positive immunoreactivity 
was found in cortical areas, hippocampus, olfactory bulb, amygdale, 
thalamus, locus coeruleus, caudate, putamen, globus pallidus and the 
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deep nuclei of the cerebellum (Shang et al., 2004; Bader at al., 2005). Within 
the Substantia Nigra, DJ-1 is localized in both neuronal and glial cells. At 
the cellular level DJ-1 immunoreactivity is found in both cytoplasm and 
nucleus, and in the mitochondrial matrix and intermembrane space 
(Zhang et al.,2005). This staining is increased in oxidative stress conditions 
suggesting that oxidation promotes the mitochondrial localization on DJ-1 
(Blackinton at al., 2005).  
 
2.2 DJ-1 functions 
 
The exact role of DJ-1 protein in health and disease remains mostly 
unknown. DJ-1 is involved in various cellular processes including cellular 
transformation, regulation of RNA stability, transcriptional activation and 
in oxidative stress response.  
Initial computational analysis revealed that DJ-1 belongs to the ThiJ-PfpI 
Superfamily containing a ThiJ domain. This domain has been first 
described in the Large Glutamine Amidotransferase superfamily (GAT), 
enzyme that is involved in the Thiamine synthesis in bacteria. However it 
is also present in chaperones, catalases and proteases. This heterogeneity 
of functions of the members of the ThiJ-PfpI superfamily limits the ability 
to predict the cellular role of the human ortholog. Structural data suggests 
that DJ-1 conformation seems to be unfavorable for catalytic activity. 
Furhermore, the catalytic triad Cys-His-Asp/Glu is not conserved across 
evolution. Olzmann et al., reported that DJ-1 exhibits protease activity 
instead of a molecular chaperone function, which is abrogated by the 
mutation of Cys106Ala. Up to know the general consensus is on the lack of 
catalase or protease activity.  
Structural comparisons between DJ-1 and Hsp31, a member of the ThiJ-
PfpI family, may point to a chaperone activity (Lee et al., 2003). 
Shendelman et al. showed that DJ-1 acts as a redox-regulated chaperone. It 
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is activated in an oxidative cytoplasmic environment and inhibits the 
formation of α-synuclein aggregates in vitro and in vivo. These data 
suggests that DJ-1 can mitigate the molecular insults downstream ROS 
burst suppressing the early step of protein aggregation.  
Zhou et al. have recently confirmed that DJ-1 chaperone activity prevents 
α-synuclein fibrillation, but only when Cys106 is oxidized to sulfinic acid 
(Cys106-SO2H), while the native DJ-1 and the highly oxidized form of DJ-1 
resulted to be ineffective. These results suggest that the oxidation level can 
affect its structure thus impairing its normal function.  
  
An intriguing hypothesis links DJ-1 to oxidative stress response. DJ-1 
undergoes a pI shift from 6.2 to 5.8 upon Reactive Oxigen Species (ROS) 
exposure, indicating that it may function as an indicator of oxidative stress 
(Taira et al., 2004). Cys 106 is the most sensitive among all the three cystein 
residues (i.e. Cys 46, Cys 53 and Cys 106). Oxidation induces a 
mitochondrial relocalization of DJ-1 and protection against cell death is 
abrogated in Cys106Ala but not by Cys46Ala or Cys53Ala (Canet-Aviles et 
al., 2004). Two post mortem studies of brain samples from PD brains found 
that acidic isoforms of DJ-1 are more abundant in PD compared to controls 
(Bandopadhway et al., 2004, Choi et al., 2006). The accumulation of acidic 
isoforms of DJ-1 monomer is followed by the enrichment of basic isoforms 
of DJ-1 dimer in PD/AD brains due to protein carbonylation (Choi et al., 
2006).  
DJ-1 displays a protective role against ROS-induced cell death. DJ-1 knock 
out by short RNA interfering rendered SH-SY5Y susceptible to both 
hydrogen peroxide (H2O2) and 1-methyl-4-phenylpyridinium (MPP+) 
(Yokota et al., 2003; Taira et al., 2004). While overexpression of wild type 
DJ-1 protects from oxidative stress, proteasomal inhibition and ER stress 
(Yokota et al., 2003; Taira et al., 2004), cells harboring Leu166Pro DJ-1 
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mutant become susceptible to death induced by hydrogen peroxide and 
do not show oxidized forms of DJ-1.  
Moreover, a number of studies performed on DJ-1 deficient mouse model 
supports this hypothesis. 
Dopaminergic neurons derived from in vitro differentiated (Martinat et al., 
2004) DJ-1-deficient embryonic stem cells showed a decreased survival 
and an increased sensitivity to oxidative stress. Comparing the responses 
to H2O2  of primary cortical neurons from brains of DJ-1 +/+, DJ-1 +/- and 
DJ-1 -/- mice embryos exposed to H2O2  (Kim et al., 2005), DJ-1 -/- 
deficient neurons showed a 20% increase in cell death compared to wild 
type DJ-1 +/+ neurons, whereas an intermediate amount of cell death was 
observed in DJ-1 +/- neurons suggesting a gene-dosage effect.  
A similar study analyzed the effect of pesticide rotenone on dopaminergic 
neurons. This pesticide inhibits mitochondrial complex I, increasing ROS. 
Upon rotenone treatment, the number of surviving dopaminergic neurons 
in DJ-1 deficient mice is decreased by 30% compared to control DJ-1 +/+ 
neurons. In addition, it has been shown that DJ-1 knock-out mice are more 
vulnerable to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and 
restoration of DJ-1 expression in DJ-1 deficient mice via adenoviral vector 
delivery mitigated cell death (Kim et al., 2005). 
Several DJ-1 KO were produced independently but none of them showed 
degeneration of dopaminergic neurons per se. Although they showed an 
age and task-dependent motor deficits, and a marked reduction in evoked 
dopamine overflow in the striatum (Goldberg et al., 2005; Chen et al., 
2005), dopaminergic neuronal loss was present only when they were 
treated with drugs that cause toxicity through mitochondrial complex I 
inhibition. 
A complementary approach to elucidate DJ-1 role in PD is the study of its 
homologs in Drosophila, DJ-1 α and DJ-β. DJ-1 α shares 56 % of homology 
with human DJ-1 and DJ-β shares 52 % identity and they are characterized 
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by distinct temporal and spatial expression pattern. Menzies et al. found 
that DJ-1 α is expressed predominantly in testis, with high expression 
level only in the late stages of development, whereas DJ-β is ubiquitously 
present, with no relevant changes in expression during the development, 
closely resembling the human DJ-1 expression pattern. Drosophila lacking 
DJ-1 activity are fertile, have a normal life span and normal number of 
dopaminergic neurons. Meulener et al. indicated that double knock out 
(DKO) is not deleterious, but it is much more sensitive to agents that 
induce oxidative stress (i.e Paraquat and Rotenone). Loss of DJ-β 
expression results in an increased survival of dopaminegic neurons due to 
a compensatory up-regulation of DJ-1 α in the brain, which is also 
associated to a decreased sensitivity to Paraquat (Menzies et al., 2005). 
Yang at al. analyzed a DJ-1 α knock out fly strain: the specific inhibition of 
DJ-1 α in dopaminergic neurons leads to a decrease of TH- positive 
neuron number, to elevated ROS accumulation and hypersensitivity to 
oxidative stress. These data clearly indicate a protective role of DJ-1 
mostly in oxidative stress response.  
DJ-1 activity is also studied through the analysis of its protein-protein 
interaction network. 
The anti-apoptotic function of DJ-1 is exerted through its interaction with 
the death protein Daxx. DJ-1 sequesters Daxx in the nucleus, preventing 
its binding and consequential activation of ASK-1 (Apoptosis Signal 
Regulating Kinase 1) (Junn et al., 2005). DJ-1 is also a transcriptional co-
regulator of several transcription factors acting on various promoters, 
functioning as a co-activator and as a co-repressor. Xu et al. demonstrated 
that DJ-1 interacts with the nuclear proteins p54nrb and pyrimidine tract-
binding protein associated splicing factor (PSF), two multifunctional 
regulators of transcription and RNA metabolism, highly expressed in 
brain. DJ-1 blocks the transcriptional silencing and apoptosis induced by 
PSF binding p54nrb and antagonizing the effect of PSF. It has been 
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proposed that mutations that can attenuate the nuclear function of DJ-1 
predispose to neurodegeneration. Interestingly, DJ-1 can activate the 
transcription at the Tyrosine Hydroxylase promoter (TH), the rate-limiting 
enzyme for dopamine biosynthesis (Jeong et al., 2006). DJ-1 prevents the 
post translational modification of PSF by the Small Ubiquitin Modifier 
SUMO-1. Mutations that abolish the sumoylation of PSF relieve the 
transcriptional repression of the TH promoter by PSF. Interestingly; the 
same study demonstrated that DJ-1 regulates sumoylation in vivo. 
Lymphoblast from PD patients (both carring deletion of exon 1-5 and the 
missense mutation Leu166Pro) have a slight reproducible increase of 
SUMO-1-modified high molecular weight complexes, compared to 
patients with wild type DJ-1 or carring the non-pathogenic mutation 
Arg98Gln. These data indicate that DJ-1 loss results in an accumulation of 
SUMO-1-modified PSF, leading to a decreased DA synthesis. It is worth 
noting that this effect is specific for SUMO-1 conjugated proteins, while it 
does not affect SUMO2/3 conjugated proteins. (Zhong et al., 2006) 
On the other hand it has been shown that DJ-1 is indispensable for the 
stabilization of the transcriptional regulator NrfII. In unstimulated 
conditions, its expression is maintained at low level by Keap-1, that targets 
NrfII to protein degradation. Upon exposure to oxidative stress, NfrII is 
translocated to the nucleus, where it forms heterodimers with other TFs 
inducing the expression of antioxidant genes whose promoters contain the 
ARE (Antioxidant Responsive Element) [Clements et al., 2006]. 
DJ-1 is also studied in Cancer. DJ-1 was first discovered as a novel 
oncogene in cooperation with activated ras (Nagakubo et al.,1997) and its 
overexpression has been reported in several cancers including breast, lung 
and prostate (Kim et al., 2005). 
Shinbo et al. found that DJ-1 is bound to p53 in vitro and in vivo and that 
this binding is stimulated by UV radiation. Moreover, DJ-1 restores p53 
transcriptional activity inhibited by Topors (Shinbo et al., 2005a), which 
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sumoylates both DJ-1 and p53. DJ-1 is sumoylated by SUMO-1 on the 
conserved Lys 130 and its post translational modification is induced by 
UV radiation in a p53-independent manner The mutant DJ-1 Lys130Arg 
abrogates cell growth-promoting activity with activated ras (Shinbo et al., 
2005b). 
Furthermore, Kim et al. 2005 demonstrated that DJ-1 modulates the 
phosphatidylinositol 3-kinase survival pathway by negatively regulating 
the function of the tumor suppressor gene PTEN. Abstrakt, an RNA 
helicase, expressed ubiquitously in all tissues, was also found to stimulate 
the transforming activity of DJ-1 in rat 3Y1 cells transfected with DJ-1 and 
activated ras (Sekito et al., 2005)  
By interacting with PIASxalpha and with DJBP, proteins predominantly 
expressed in testis, DJ-1 was also able to alter their DJ-BP binding to the 
Androgen Receptor (AR) ( Takahashi et al., 2001). 
PIASxalpha directly binds to AR in a testosterone-dependent manner and 
it negatively modulated the AR transcription activity by recruiting the 
histone-deacetylase complexes. DJ-1 antagonizes this inhibition by the 
abrogation of the complex and restoring the AR activity.  
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2.3 DJ-1 in Neurodegeneration 
 
Immunohistochemical staining for DJ-1 labels Tau inclusions found in 
several neurodegenerative disorders, including Alzeheimer’s disease 
(AD), Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia 
linked to chromosome 17 (FTDM-17), and Pick’s Disease (PiD) 
(Bandopadhyay et al., 2004; Neumann et a., 2004; Rizzu et al., 2004). 
Furthermore, DJ-1 antibodies readily label α-synuclein glial cytoplasmic 
inclusions observed in patients with Multisystem Atrophy (MSA) 
(Neumann et al., 2004) and PD. As with tau and α-synuclein, a fraction of 
DJ-1 protein becomes markedly insoluble in brain from AD, PiD and MSA 
compared to controls. (Neumann et al., 2004; Rizzu et al., 2004). Moore et al. 
monitored the level of detergent-soluble DJ-1 in human post mortem 
cingulated cortex tissue. They found a dramatic increase of DJ-1 levels in 
the detergent-insoluble fraction in PD and Dementia with Lewy Bodies 
(DLB), indicating that in pathological conditions DJ-1 can undergo a 
biochemical modification. These data support the notion that different 
neurodegenerative diseases might share a common mechanism in which 
DJ-1 role needs to be elucidated. 
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3  SUMOYLATION 
 
Small Ubiquitin Modifiers (SUMO), an highly conserved protein family 
found in all eukaryotes, has been shown to be responsible of post 
translational modification. It belongs to the Ubiquitin Like Proteins (UBLs) 
superfamily, since it shares structural similarity with ubiquitin (Bayer et 
al., 1998) and is mechanistically involved into the transfer of small protein 
moieties onto various substrates, modulating a growing number of 
cellular pathways.  
SUMOs shares only 18% sequence identity with Ubiquitin and their 
molecular weights are around 11 kDa, but they could appear larger on 
SDS-PAGE adding around 20 kDa to most substrates. While yeast and 
invertebrates contain a single SUMO gene, vertebrates contain four 
different genes: SUMO-1 (also known as sentrin, PIC1, GMP1, Ubl1 and 
Smt3c), SUMO-2 (sentrin-3, Smt3a), SUMO-3 (sentrin-2, Smt2b) and 
SUMO-4. SUMO-1 mainly exists in conjugated form, whereas SUMO-2 
and SUMO-3 mostly in free form. SUMO-2 and SUMO-3 share ∼95% 
sequence identity and are 50 % identical to SUMO-1 (figure 5). They are 
generally regarded as being functional equivalent, being the main 
differences clustered at their C-terminal region. At the level of their N-
terminal they contain the ψKXE sequences, which can serve as SUMO 
attachment sites, allowing the formation of SUMO chain in vitro and in 
vivo. This sequence is lacking in SUMO-1, inhibiting the formation of poly-
SUMO-1 chain. Recently, another member of the superfamily, SUMO-4, 
has been identified. Its messenger is shown to be mainly expressed in 
kidney cells (Bohren et al., 2004). However this intronless gene has been 
suggested to be one of numerous SUMO-3 pseudogenes, as the expression 
of the endogenous protein has yet not been demonstrated. Further studies 
are required to resolve this issue and establish the functional role of 
SUMO-4. 
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Fig 5: Aligment of nucleotide and encoded amino acid sequences of human SUMO 1/ 
2/3. The inverted triangles indicate the position of introns (Su et al., 2002). 
 
3.1 Mechanism of SUMO conjugation 
 
SUMO protein conjugates are formed as the result of serial reactions with 
no apparent discrimination among all SUMOs (figure 6). 
SUMOs form from inactive precursors: the maturation occurs by a 
carboxy-terminal proteolityc cleavage that exposes di-glycine residues.  
This reaction is catalyzed by the heterodimer E1-activating enzyme 
Aos/Uba2.  
In detail, the E1 activating enzyme uses ATP to form a bound SUMO-
adenylate via the di-glycine of the SUMO protein. Then, a cystein in the 
active site of Uba2 subunits interacts with the SUMO-adenylate, releasing 
AMP and forming an high energy thioester bond. The sumo moiety is then 
transferred in a second step to the E2-conjugating enzyme, Ubc9, via a 
trans-esterification reaction, forming the Ubc9-SUMO thioester complex 
through Cys93.  
Ubc9, the only SUMO-conjugating enzyme in yeast and invertebrates and 
most likely in vertebrates as well, is able to recognize the substrate protein 
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itself. It subsequently catalyzes the formation of isopeptide bond between 
the Gly of SUMO and the ε-amino group of the target lysine residue. The 
lysine is usually found within a SUMO modification consensus motif, 
ψKXE/D (where ψ is a large hydrophobic residue and X any residue), the 
major element from target proteins that bind directly to Ubc9 (Lin D.et al., 
2002; Johnson et al., 2004). 
Although all targets interact with Ubc9, an efficient conjugation requires 
the presence of the additional factor E3-ligase. Even if it doesn’t increase 
the rate of sumo-conjugation in vitro, it has been shown to be an important 
regulator of the modification in vivo. 
Indeed, it might increase the affinity of Ubc9 for a specific target through 
the recognition of the surrounding regions near the SUMO consensus 
motif, contributing mechanistically to conjugation.  
Three different E3-SUMO ligases have been discovered: the PIAS (Protein 
Inhibitor of Activated Stat) family, RanB2/Nup358 and the polycomb 
group protein PC2.  
RanBP2 is required for the sumoylation of RanGAP-1 and it is not known 
if it may promote the modification of other proteins as well. PC2 belongs 
to the PcG proteins, a multimeric complex involved in histone methylation 
activity and in transcriptional repression. Four mammalian genes 
encoding PIAS have been also described: PIAS1, PIAS3, PIASx and PIASy. 
PIAS3 have a splice variant called KChaP, and PIAS also produces two 
isoforms derived from alternative splicing, designated PIASxα and 
PIASxβ. PIAS1 and PIAS3 are found in all cell types, whereas PIASx and 
PIASy appear to be expressed primarily in testis. However, all PIAS 
localize to intranuclear dots, which are, at least in part, PML nuclear 
bodies.  
Further studies are required to characterize the substrate specificity of the 
PIAS proteins, but the emerging evidence is that they have different 
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substrates specificities (Miyauchi et al., 2002) and promote attachment of 
different SUMO isoforms. 
The pattern of SUMO conjugation is dynamic and changes during the cell 
cycle and in response to various stimuli. Since sumoylation is involved in 
different cellular pathway, its not surprising that it is a reversible process. 
The deconjugation is catalyzed by SUMO-cleaving enzymes (called 
isopeptidases or SENPs), that have at least two functions in this process. 
They remove SUMO from proteins, and providing an additional source of 
free SUMO to be used to modify other targets. Both these sources of free 
SUMO are likely to be critical in maintaining normal levels of SUMO 
conjugation, considering that cellular pools are very low.  
Up to now seven different SENPs protein have been identified: they have 
different N-terminal domains and different cellular localization, 
suggesting that they may desumoylate different proteins.  
SENP6 (SUSP1) is primarily found in the cytoplasm, SENP1 localizes to 
foci in the nucleus and the nuclear rim, SENP3 (SMT3IP1) and SENP5 are 
localized in nucleolus. For SENP2 (Axam, SMT3IP2/Axam2, SuPr-1) there 
are at least three different isoforms derived from alternatively splicing that 
mainly differ at the level of the N-terminal: this extended region of the 
SENP2/Axam allow to bind the nucleoplasmic side of the nuclear pore 
complex, while Axam2/SMT3IP2 localizes to the cytoplasm and SuPr1 
lacks these N-terminals localizing to PML nuclear bodies. 
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Fig 6: Schematic representation of SUMO conjugation and deconjugation. 
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3.2 Substrate specificity in SUMOylation 
 
As anticipated, Sumo is attached to most substrates by a lysine residue, 
belonging to ψKXE/D consensus sequences. However additional 
determinants are involved in substrate selection. Inside the consensus 
sequence, the glutamic acid is the most highly conserved position for the 
lysine. In some cases even the conservative Glu to Asp mutation 
significantly reduces sumoylation (Sapetschning et al., 2002), although few 
ψKXD sequences are sumoylated.  
Considering that the ψKXE/D sequence is very short, it can be easily 
found in many proteins, most of which are probably not modified by 
SUMO. On the other hand, increasing experimental data show that 30% of 
real sumoylation sites don’t follow this consensus and several proteins are 
also modified at other sites than ψKXE/D.  
The replication processivity factor PCNA presents two sumoylation sites, 
one with the consensus sequence and the other with the TKET sequence 
(Hoege et al., 2002). In addition it has been reported that TEL, PML, Smad4 
and the Epstein Barr virus BZLF1 protein sumoylation site are respectively 
TKED, AKCP, VKYC and VKFT, while in Axin both lysines in a GKVEKVD 
sequence are sumoylated. Moreover, some sumoylated proteins (i.e. 
Mdm2, Daxx, CREB, and CTB-2) do not contain a ψKXE/D and others are 
still sumoylated when all consensus sites are mutated (Rangasamy et al., 
2000; Jang M.S. et al., 2002; Miyauchi et al., 2002; Comerford et al., 2003;). 
It’s still not known how these “non consensus sites” are recognized. It has 
been hypothesized that different E1-activating enzyme can cleave and 
activate distinct SUMOs pools upon specific cellular pathway.  
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3.3 Substrates and functions of SUMO protein 
modification 
 
Since its discovery in 1996, SUMO has received a high degree of attention 
because of its intriguing and essential functions, and because its substrates 
include a variety of biomedically important proteins such s p53, c-Jun, 
PML and Huntingtin.  
SUMO modification alters the activity and the ability of the target proteins 
to interact and plays an important role in diverse processes such as 
chromosome segregation and cell division, DNA replication and repair, 
nuclear import, protein targetting to and formation of certain subnuclear 
structures. 
 
3.3.1 Role of SUMO in cytosol/nucleus trafficking 
 
The mammalian protein RanGAP1 is identified as the first substrate for 
SUMO-1 modification (Matunis et al., 1996). RanGAP1 is a GTPase-
activating protein for the small nuclear Ras-Realated GTPase Ran, whose 
function is essential for transport of proteins into the nucleus across the 
nuclear pore complex. Here RanGAP1 is highly concentrated and forms a 
stable complex with RanBP2, a component of cytoplasmic filaments in the 
nuclear pore complex. The interaction between RanGAP1 and RanBP2 
requires Sumoylation. The replacement of Lys-526 by Arg in RanGAP1 
prevents the localization of the protein to the nuclear rim, resulting in its 
cytoplasmic accumulation (Mahajan et al., 1997). Sumoylation may induce 
conformational changes in the C-terminal of RanGap1 that exposes or 
creates a binding surface for RanBP2. 
In support of this hypothesis, it has been shown that the nuclear import of 
a number of proteins (i.e. CtBP, the bovine papillomavirus E1 protein, Elk-
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1) depends on their modification with SUMO (Lin et al., 2003; Rangasamy 
D. et al., 2000, Salinas et al.,2004 ). However, there are also examples of 
proteins (i.e. TEL and DdMEK-1) whose export from the nucleus 
dependson their sumoylation (Wood et al., 2003; Sobko et al., 2002). 
 
3.3.2 Role of SUMO in protein targeting to subnuclear 
structures 
 
PML is a RING-finger protein with tumor suppressor activity. In the 
majority of the patients with acute promyelocytic leukaemia, the PML 
gene has undergone a fusion with the retinoic acid receptor α gene 
(RARα) by a chromosomal translocation, yielding a chimeric PML/RARα 
protein.  
PML is enriched in subnuclear-matrix associated structures, called the 
PML nuclear bodies, or ND10 (Nuclear Domain 10) or PODs (PML 
Oncogenic Domains). The SUMOylated PML is preferentially targeted to 
the nuclear bodies, whereas the unmodified form remains in the 
nucleoplasmic fraction.  
SUMOylation is also required for the nuclear bodies localization of several 
other proteins, including Sp100, Daxx and CBP. Interestingly, nuclear 
bodies fail to form when mutant PML that cannot be SUMOylated is 
expressed into PML -/- cells. This indicates a role of SUMO modification 
of PML in the formation of PODs and in recruiting other nuclear body 
proteins. With the exception for Sp3 (Ross et al., 2002), the localization of 
most proteins to PML bodies (i.e Sp100, Daxx, Topors, Lef1, Hsf2) doesn’t 
depend on their SUMOylation (Jang M.S. et al., 2002; Sternsdorf T. et al., 
1999; Weger S .et al.,2003; Goodson M.L. et al., 2001). 
Interestingly, PML is also modified by SUMO-2/3 (Kamitani et al., 1998). 
Both the conjugation and the olygomerization of SUMO-3 to PML are 
essential for its stable nuclear localization. Since the modification occurs 
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on Lys160 for both SUMO-1 and SUMO-2/3, it has been proposed that 
SUMO-1 may act as SUMO-3 polymeric chain terminator (Fu et al., 2005). 
 
SUMO modification of homeodomain-interacting protein kinase 2 
(HIPK2) and TEL induces formation of the nuclear speckles, a different 
subnuclear structure. HIPK2 is a nuclear protein kinases that acts as 
corepressor of homeodomain transcription factors. TEL is a transcription 
factor required for hematopoiesis within the bone marrow. The 
SUMOylated TEL localizes to the nuclear speckles in a cell cycle-specific 
manner (Chakrabarti et al.,2000) and in both cases mutations of lysines 
residue in the SUMO acceptor site impair the specific nuclear spleckle 
formation.  
 
3.3.3 Role of SUMO in the regulation of 
transcriptional factors 
 
As anticipated, the PML sumoylation is followed by the recruitment of 
specific proteins to the nuclear bodies, which are involved in the 
modulation of transcriptional activity. 
P53 is a target for SUMO-1 modification (Gostissa et al., 1999). Upon 
exposure of cells to UV, SUMO-1 is covalently attached at Lys 386, that is 
located in the C-terminal of p53. The modification of this region induces 
p53 transcriptional and apoptotic activity. 
Similar results were also recently obtained with SUMO-2/3, which can 
modify p53 at the same Lys of SUMO-1, activating its transcriptional 
activity (Li et al., 2006). 
Sumoylation was initially associated to transcriptional inhibition, as for c-
Jun and AR. The mutations of the sumoylation sites in these proteins (Lys 
to Arg substitutions) were shown to enhance their transcriptional activity, 
suggesting a negative modulation by sumoylation.   
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An increasing number of transcriptional repressors and activators whose 
activity is regulated by sumoylation are identified. Considering that the 
effect of sumoylation differs according to the specific target, it is probably 
involved in the transcriptional regulation by multiple mechanisms. 
 
3.3.4 SUMO as an inhibitor of ubiquitin-mediated 
degradation 
 
It has been shown that sumoylation plays an additional role in 
antagonizing ubiquitin conjugation, as demonstrated for NF-kB, Mdm2, 
and Huntingtin.  
NF-kB, a transcription factor involved in the regulation of the immune 
function, inflammatory response, cell adhesion and growth control, is kept 
inactive by its inhibitory protein, IkBs, in unstimulated cells. Upon 
stimulation by effectors (i.e. proinflammatory cytokines, phorbol esters, 
oxidants) IkBs is first phosphorylated; then upon poly-ubiquitination it is 
rapidly targeted for degradation by the 26S proteasome. Interestingly, 
SUMO-1 can be conjugated at the same ubiquitination sites with a 
consequent stabilization against degradation (Desterro et al., 1998).  
 
3.3.5 SUMO and the cell cycle 
 
Mutations in the SUMO conjugation system in S. Cerevisiae have revealed 
the importance of this protein modification for normal execution of cell 
cycle. Mutants deficient in SUMO conjugation accumulate at G2/M in the 
cell cycle with duplicated DNA content, unseparated sister chromatids 
and undivided nuclei (Biggins S. et al., 2001; Dieckhoff P., 2004). Many 
SUMO targets have been discovered, such as Top2, Pds5, PCNA, septins 
in yeast, as well as TOPII in mammalian cells. These proteins are 
sumoylated in a cell cycle-controlled manner indicating that SUMO 
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modification serves to synchronize the function of many of its substrates 
with the cell cycle. Substrates are modified in different phases of cell cycle: 
for example, PCNA is modified in S phase (Hoege et al.,2002),  whereas 
septins in G2/M (Johnson et al., 1999). How the modification of these 
substrates is regulated respect to the cell cycle it is still not clear. 
 
3.3.6 SUMO in DNA damage repair  
 
Genetic data obtained with yeast mutants defective in the SUMO cycle 
implicate SUMO modification in the DNA damage response. In mammals 
PCNA provides a direct link of SUMO to the DNA repair processes. Upon 
lethal exposure of methyl methansulfonate PCNA is modified by the 
attachment of SUMO in the S-phase of the cell cycle. Interestingly, the 
same Lys that is acceptor of SUMO, may be also Ubiquitinated, but this 
process doesn’t target PCNA for degradation but it activates PCNA in 
DNA repair processes. Moreover, preventing this modification, as in 
Lys164Arg, it provokes an increase in the DNA damage sensitivity of cells 
that are unable to ubiquitinate this site (Hoege et al.,2002). Alternatively 
sumoylation may restrict PCNA to engage in DNA replication, inhibiting 
DNA repair and inducing mutagenesis (Haracska L et al., 2004) . 
 
3.4 Proteomic approach to SUMO-2/3 substrates 
 
The identification of the entire spectrum of proteins modified by 
sumoylation is required to better define the range of cellular events 
regulated by sumoylation. It is not clear, however, whether different 
SUMO family members have a unique cellular role or they act in a 
redundant manner. Further investigations are needed especially for 
SUMO-2 and SUMO-3, since they share 95% of homology and since their 
substrates are largely unknown.  
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Table 2 shows a list of SUMO-2/3 protein substrates known so far. They 
are divided according to the method of identification. As “tagged” we 
refer to a proteomic approach from stable transfected cell lines with 
SUMO-2 and/or SUMO-3 cDNAs fused in frame with the tagged 
sequence used for the purification (HA/6x-His tag). In “ectopic”, transient 
co-transfections of SUMO-2/3 and potential cDNA targets are carried out. 
As ”endogenous”, we indicate proteins that are identified as sumoylated 
within living cells with no experimental manipulations. Very few 
endogenous SUMO-2/3 targets are known. 
 
 
Table 2A: Schematic list of SUMO-2 modified proteins known so far. a) Vertegaal et 
al., 2006; b) Vertegaal et al., 2004; c) Acosta et al., 2005; d) Kamitani et al., 1998; e) Fu et 
al., 2005; f) Eaton et al., 2004; g) Li et al., 2006; h) Azuma et al., 2005; i) Šramko et 
al.,2006; j) Dorval et al., 2006. 
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Table 2B: Schematic list of SUMO-3 modified proteins known so far. . a) Vertegaal et 
al., 2006; b) Vertegaal et al., 2004; c) Acosta et al., 2005; d) Kamitani et al., 1998; e) Fu et 
al., 2005; f) Eaton et al., 2004; g) Li et al., 2006; h) Azuma et al., 2005; i) Šramko et 
al.,2006; j) Dorval et al., 2006. 
 
3.5 SUMOylation and Oxidative stress 
 
Various stress (heat shock, oxidative and osmotic stress) have been shown 
to increase global SUMO-conjugation, in particular for SUMO-2 and 
SUMO-3. It has been also reported that ROS (reactive oxygen species) at 
low concentration lead to a rapid diseapperance of most SUMO-
conjugates. This is due to direct and reversible inhibition of SUMO 
conjugating enzymes through the formation of di-sulfides bonds involving 
the catalytic Cysteins of the SUMO E1 subunits Uba 2 and the E2 
conjugating enzyme Ubc9. (Bossis and Melchior., 2006). These findings 
add SUMO proteins and the SUMO conjugating enzyme to the list of 
specific direct effectors of H2O2 and implicated ROS as Key regulators of 
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Sumoylation-Desumoylation equilibrium. ROS, such as superoxide (O2 -  ), 
hydrogen peroxide (H2O2 ) and hydroxyl radicals (.OH) are constantly 
produced in the human body by metabolism and are also generated 
intracellularly after exposure to UV, ionization radiation, 
chemiotherapeutic agents. The deregulation of cellular redox status is a 
causal agent in numerous degenerative disorders such as Alzheimer 
disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’ s 
disease (PD). 
 
3.6 SUMOylation and neurodegeneration 
 
Considering that SUMO pathway controls a number of important 
regulatory molecules, it can promote both the cell survival and 
dysfunction leading to cell death. While most studies focused on its role in 
normal cell metabolism, several recent reports have implicated this 
pathway in neurodegeneration.  
Since many SUMO acceptors proteins are nuclear, is not surprising that 
first evidences linking SUMOylation to neurodegeneration were 
discovered on disorders characterized by intranuclear protein aggregates. 
Pountney et al. presented evidence that SUMO-modified proteins 
accumulate in the Intranuclear aggregates of Neuronal Intranuclear 
Inclusion Disease (NIID), even if the identity of the SUMO-modified 
protein is still to be determined. Increasing sumoylation has been 
observed in brain tissue from Spinocerebellar Ataxia type 3 (SCA3) and in 
Dentatorubral-pallidoluysian atrophy (DRPLA) (Terashima et al., 2002; 
Ueda et al., 2002). In a neuronal model of DRPLA, co-expression of wild 
type SUMO-1 with PolyQ-Atrophin-1 significantly accelerates the 
formation of nuclear aggregates and promotes apoptosis. On the other 
hand, expression of the conjugation-deficient SUMO promoted cell 
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survival compared to the mutant PolyQ protein alone or in the presence of 
wild type SUMO-1.  
One proposed mechanism involves the sequestration of SUMO-modified 
proteins in the nucleus or their accumulation via non-covalent binding 
motifs. The recruitment of SUMO monomers or sumoylated substrates 
into inclusions could further exacerbate the sequestration of cellular 
components critical for neuronal survival.  
An interesting hypothesis suggests that competition between SUMO and 
Ubiquitination may avoid the degradation of mutant atrophin-1. This 
theory was first demonstrated for a pathogenic fragment of Huntingtin 
(Htt) (Steffan et al., 2004). Expression of a permanent, non hydrolyzable 
Htt-SUMO conjugate in a neuronal cell line resulted in a more stable 
protein and potentially increases the level of toxic oligomers. The Lys 
modified by SUMO-1 is also the acceptor site for Ubiquitin, leading to a 
competition between the two modifiers. In the same model, Htt displayed 
an increased transcriptional repression. Therefore, the sumoylation 
occuring in the N-terminal domain of the protein may mask the 
cytoplasmic retention signal and promote nuclear localization.  
The cellular models for HD and DRPLA have suggested an exacerbating 
role of sumoylation in neurodegeneration. The opposite has been 
proposed for another polyglutamine disease, the Spinal Bulbar Muscular 
Atrophy (SBMA). In Drosophila, expression of the catalytic-deficient C175S 
mutant form of the SUMO-activating enzyme (E1) subunit Uba2 greatly 
enhances degeneration. Similar observation is obtained for the Machado-
Joseph-Disease (MJD), suggesting that down-regulation of SUMO 
modification is detrimental to cells.  
Synucleinopathies are a group of neurodegenerative diseases 
characterized by accumulation of filamentous aggregates of α-synuclein in 
cytoplasmic inclusions. This group includes PD, Dementia with Lewy 
Bodies (DLB) and Multiple System Atrophy (MSA). SUMO-1 
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immunoreactivity has been reported in MSA oligodendroglial cytoplasmic 
inclusions as well as punctuated staining at the nuclear membrane level. 
Similar to the poly-Q diseases the colocalization raised the question of the 
identity of the targets within aggregates. It has been recently reported that 
α-synuclein is substrate for SUMO-1, and less for SUMO-2/3, providing a 
direct link for the pathogenic deposit. (Dorval et al., 2006)  
Since, several genes involved in the pathogenesis of PD are closely linked 
to the Ubiquitin proteasome system, recent data on the interplay between 
SUMOylation and Ubiquitination are of major interests. 
Parkin is an Ubiquitin E3 ligase that is involved in the turnover of the 
SUMO E3 ligase RanBP2, catalyzing its ubiquitination and promoting 
proteasome degradation. More recently a functional non-covalent 
interaction between Parkin and SUMO-1 has been reported, which results 
into parkin nuclear localization and auto-ubiquitination.  
In the case of Alzheimer’s Disease (AD), SUMO-3 overexpression reduced 
Aβ production whereas expression of SUMO mutants that cannot be 
conjugated or form polymeric chains increases the production of 
amyloidogenic peptides (Li et al., 2003). In contrast, a more recent study 
investigating the effect of overexpression of the three major SUMO 
isoforms on the APP processing pathway showed that SUMO-3 increases 
the generation of Aβ (Dorval et al., 2007).  
Intriguingly, the misregulation of SUMO conjugation may result in 
loss/gain of function of proteins that contribute to a diminished survival 
of neurons.  
In PD, α-synuclein and DJ-1 are substrates for SUMOylation (Dorval et al., 
2006; Shinbo et al., 2005b). DJ-1 is modified at Lysine 130 and this 
modification is stimulated by both PIASxα and PIASy, confirming that 
they may act as E3 ligase for DJ-1. Previously, it was reported that DJ-1 
acts as a positive regulator for the Androgen Receptor (AR) by 
sequestering PIASxα (Takahashi et al., 2001), which functions as negative 
 37 
regulators for AR by preventing AR DNA-binding activity. While the role 
of Sumoylation has been investigated in the DJ-1 transforming activity, 
Shinbo et al. have found that the PD-related DJ-1 Leu166Pro can be 
improperly sumoylated as compared to its wild type counterpart. This 
was evident by the presence of higher molecular weight DJ-1/SUMO 
positive bands and suggested that the mutant protein may be 
polysumoylated on selected lysine or sumoylated on multiple lysines.  
The SUMO conjugation on DJ-1-Leu166Pro may promote aggregation 
leading to high molecular weight species, insolubility, change in 
subcellular localization and instability (figure 7). 
The DJ-1-Leu166Pro mutant and to less extent, the DJ-1 Lys30Arg are 
more sensitive to oxidative stress induced by UV radiation.  
This implicates a role of DJ-1-SUMOylation in the response to cellular 
insults but the relationship between SUMO, DJ-1 and oxidative stress 
appears increasingly complex.  
In conclusion, SUMO modification may be involved in neurodegeneration 
by different mechanisms: the modification of a substrate can affect its 
subcellular localization and sumoylated substrates can sequestrate critical 
proteins in virtue of the Sumo Binding Motif (SBM). SUMO can then 
contribute to the formation of inclusions in the case of a decrease solubility 
of the protein, as well as, it may antagonize the proteasomal degradation 
and protein turnover.  
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Figure 7: SUMO effects on DJ-1 and its relationship to oxidative stress: the 
modification could interfere with DJ-1 function and may lead to cellular sensitivity to 
oxidative stress (Dorval et al., 2007).
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 MATERIALS AND METHODS 
1 CELL LINES AND CULTURE CONDITIONS 
 
HEK293T (Human Embryonic Kidney) and COS-7 (African Green Monkey 
SV40-transformed kidney fibroblast cell line) cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% foetal 
bovine serum (FBS), 100 μg/ml Streptomycin and 100 U/mL Penicillin at 
37°C in a humidified CO2 incubator. SH-SY5Y (Human neuroblastoma cell 
line), were cultured in F-12 Nutrient Mixture (Ham) and EMEM (modified 
Eagle’s medium) in a volume ratio 1:1, 15% FBS, 1% NEAA (Non Essential 
Aminoacid), 2 mM Glutamine and 100 μg/ml Streptomycin and 100 
U/mL Penicillin at 37°C in a humidified CO2 incubator. 
 
2 PLASMIDS 
2.1 Cloning wild type SUMO-2 and wild type 
SUMO-3 into pcDNA3-vector 
 
cDNAs for SUMO-2 and SUMO-3 coding sequences (cds), gift of Prof G. 
Del Sal (LNCIB, Trieste) were amplified by Polymeric Chain Reaction 
(PCR) using specific primers with BamHI and EcoRI restriction sites on the 
5’ and 3’ primers respectively. 
 
Primers. 
Wild Type SUMO-2. 
Forward: 5’ -GGG GAT CCA TGG CCG ACG AAA AGC CCA AG-3’ 
Reverse: 5’-AAG AAT TCT CAG TAG ACA CCT CCC GTC TG-3’ 
Wild Type SUMO-3 
Forward: 5’ GGG GAT CCA TGT CCG AGG AGA AGC CCA AG-3’ 
Reverses 5’- AAG AAT TCC TAG AAA CTC TGC CCT GCC AG-3’ 
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After PCR amplification and removal of primers and enzyme by the PCR 
purification kit (Qiagen), each PCR product was digested by BamHI and 
EcoRI for 2 hours at 37ºC. After another step of purification of the digested 
fragments by PCR purification kit, each of them has been cloned 
directionally BamHI and EcoRI in the vector pcDNA3-HA, digested with 
the same restriction enzymes. 
 
2.2 PCR Site-Directed Mutagenesis of SUMO-2 
and SUMO-3: creating the unconjugable forms 
 
The wild type SUMO-2 and wild type SUMO-3 cds were further used to 
obtain unconjugable SUMO-2 and SUMO-3 proteins with the strategy of 
PCR Site-Directed Mutagenesis. In particular the di-Gly at the C-terminal 
motif was converted into a di-Ala motif.  
One PCR reaction was required for SUMO-2. 
Primers 
Unconjugable SUMO-2 (SUMO-2GG92/93AA) 
Forward: 5’ -GGG GAT CCA TGG CCG ACG AAA AGC CCA AG-3’ 
Reverse: 5’-AAG AAT TCT CAG TAG ACA GCT GCC GTC TG-3’ 
 
For the unconjugable form of SUMO-3, two PCR reactions with were 
required to amplify two different overlapping fragments. They were 
purified by Gel Extraction kit (Qiagen) and subsequently annealed with a 
third PCR. The first PCR amplifies SUMO-3 from nucleotide 1 to 
nucleotide 294 with the forward primer previously described inserting the 
BamHI restriction site at 5’ end. The reverse primer (GG90/91AA) was 
used to introduce the mutations. On the template obtained, purified by 
Gel Extraction, a second PCR was performed with the same forward 
primer and a second reverse primer (EcoRI) to introduce the EcoRI 
 41 
restriction site. The PCR product fragment was further subcloned into the 
pcDNA3-HA vector. 
 
Primers 
Unconjugable SUMO-3 (SUMO-3GG91/921AA) 
Forward: 5’ GGG GAT CCA TGT CCG AGG AGA AGC CCA AG-3’ 
Reverse GG90-91AA: 5’-CAG GCT GCT CTC CGG CAC AGC TGC CGT 
CTG-3’ 
Reverse EcorRI: 5’-AAG AAT TCC TAG AAA CTC TGC CCT GCC AGG 
CTG CTC TCC GGC AC-3’ 
 
2.3 PCR Site-Directed Mutagenesis of DJ-1: 
strategy to obtaine different DJ-1 Lysine mutants 
replaced by Arginine 
 
cDNAs encoding the DJ-1 mutants K4R, K12R, K32R, K41R, K62-63R, K89-
93R, K99R, K122R, K130R, K132R, K148R, K175R, K182R, K187R were 
generated by PCR Site Directed mutagenesis and the respective cDNAs 
were cloned by EcoRI and XbaI restriction into a 2X-Flag-pCDNA3 vectors. 
The following sets of overlapping primers were used to introduce the 
mutation. 
Primers 
DJ-1 K4R: 
Forward: 5’-ATA TAG AAT TCG CTT CCA GAA GAG CTC TGG-3’ 
DJ-1 K12R: 
Forward: 5’-TCC TGG CTA GAG GAG CAG A-3’ 
Reverse: 5’-TCT GCT CCT CTA GCC AGG A-3’ 
DJ-1 K32R: 
Forward: 5’-GCT GGG ATT AGG GTC ACC GTT-3’ 
Reverse: 5’-ACC GGT GAC CCT AAT CCC AGC-3’ 
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DJ-1 K41R 
Forward: 5’-TGC AGG CCT GGC TGG AAG AGA C -3’ 
Reverse: 5’-ACT GTA CTG GGT CTC TTC CAG C-3’ 
DJ-1 K62/63R 
Forward: 5’-CCT TGA AGA TGC AAG AAG AGA G-3’ 
Reverse: 5’-ATG GTC CCT CTC TTC TTG CAT C-3’ 
DJ-1 K89/93R 
Forward: 5’-GCT GTG AGG GAG ATA CTG AGG GAG CAG-3’ 
Reverse: 5’-CTG CTC CCT CAG TAT CTC CCT CAC AGC-3’ 
DJ-1 K99R 
Forward: 5’-GAA AAC CGG AGG GGC CTG ATA-3’ 
Reverse: 5’-TAT CAG GCC CCT CCG GTT TTC-3’ 
DJ-K122R 
Forward: 5’-TGG AAG TAG AGT TAC AAC ACA C-3’ 
Reverse: 5’-GTG TGT TGT AAC TCT ACT TCC A-3’ 
DJ-1 K130R 
Forward: 5’-CAC ACC CTC TTG CTA GAG ACA AAA TGA TG-3’ 
Reverse: 5’-CAT CAT TTT GTC TCT AGC AAG AGG GTG TG-3’) 
DJ-1 K132R 
Forward: 5’-CTT GCT AAA GAC AGA ATG ATG AAT-3’ 
Reverse: 5’-ATT CAT CAT TCT GTC TTT AGC AAG-3’ 
DJ-1 K148R 
Forward: 5’-GAA TCG TGT GGA AAG AGA CGG C-3’ 
Reverse: 5’-GAA TCA GGC GTC CTC TTT CCA C-3’ 
DJ-1 K175R 
Forward: 5’- TGA ATG GCA GGG AGG TGG C-3’ 
Reverse: 5’-GCC ACC TCC CTG CCA TTC A-3’ 
DJ-1 K182R 
Reverse: 5’-GCG CGT CGA CGT CTT TAA GAA CAA GTG GAG CCC 
TCA-3’ 
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DJ-1 K187R 
Reverse: 5’ GCG CGC TCT AGA CTA GTC TCT AAG AAC AAG TGG-3’ 
 
To amplify the whole DJ-1 cDNA in which Lys were replaced by Arg, two 
external sets of primers were used. The forward, (5’-ATA TAG AAT TCG 
CTT CCA AAA GAC CTC TGG-3’) introduced the EcoRI restriction site, 
and the reverse one the XbaI site (5’-GCG CGC TCT AGA CTA GTC TTT 
AAG AAC AAG TGG-3’). Overlapping PCR products were purified by 
Gel Extraction, subjected to annealing, and finally to a third PCR using 
external primers. 
 
3 TRANSFECTIONS 
 
Transient transfections were performed by standard calcium phosphate 
precipitation method. A transfection mix was prepared by 0.25 mM CaCl2, 
plasmid DNA, HEPES Buffered Saline Solution (2X Stock Solution: 140 
mM NaCl, 1, 5 mM Na2HPO4*2H2O, 50 mM HEPES pH7.1). The 
CaCl2/DNA solution was added dropwise to the 2X HEPES Buffered 
Saline Solution while gently vortexing. The mixture was incubated at 
room temperature (R.T.) for 45 minutes, and then it was gently added to 
cells. HEK293T, seeded 24 hrs before transfection at 50-60% confluency, 
were further incubated with precipitates over night (O.N.). Precipitates 
were removed washing with Phosphate Buffered Saline (PBS) and 
transfected cells were further incubated for 24 hrs with fresh medium. For 
the sumoylation assay, 300.000 HEK293T were seeded the day before on 6-
multiwell plate and transfected with 3 μg of total DNA: 1 μg 2X-Flag-DJ1, 
1μg HA-SUMO-2/3 in conjugable or unconjugable forms and 1 μg HA-
Ubc9 (gift of Dr. L. Collavin) in different combinations. Similar 
experiments were initially perfomed with GFP-SUMO-1 and the truncated 
unconjugable form GFP-SUMO-1 Δ6 provided by Dr. Collavin L. and Prof. 
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Del Sal G. All the 2X-Flag-DJ-1 lysines mutants were co-transfected with 
HA-Ubc9 and HA-SUMO-3 conjugable/unconjugable in ratio 1:1:1. 
For the immunoprecipitation experiments 2.000.000 HEK293T were 
seeded on 10-cm2 dishes and 21 μg of total DNA were transfected (7 μg of 
DNA for each plasmid). The same amount of cells was transfected with 7-
10 μg of HA-Ubc9 to demonstrate its interaction with endogenous DJ-1. 
After 48 hrs the expression of exogenous proteins was analyzed by 
Western Blot Analysis or Immunoprecipitation experiments. 
 
4 TREATMENTS 
 
Titration and time course experiments were done on 90 % confluent SH-
SY5Y cells using different drugs that rapresent an in vitro neurochemical 
model of PD. 600.000 cells were seeded 24 hours before. 
Treatments were performed as follows 
• H2O2 : 0.01 mM, 0.1 mM, 1 mM, 5 mM, 10 mM, 100 mM for 30 
minutes and 1 mM, 10 mM for 1 hour;  
• MG-132: 0.25 μM, 0.5 μM and 5 μM MG-132 for 1 hour and 24 hours 
using as control the respective amount of the vehicle, DMSO;  
• Dopamine (DA) and 6-OHDA (6-OHDA): 10 μM, 100 μM, 250 μM, 
500 μM for 24 hours and 500 μM and 1mM for 1 hour. 
• 1-methyl-4-phenylpyridinium (MPP+): 50 mM for 1 hour. 
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5 PROTEIN ANALYSIS 
5.1 Western Blotting Analysis 
 
For the Sumoylation analysis, transfected HEK293T and SH-SY5Y in 6-
multiwell were washed carefully with ice-cold PBS supplemented with 10 
mM NEM (N-Ethylmaleimide) and 10 mM IAA (Iodoacetamide) and lysed 
directly into 200 μl of hot 2X Laemmly Buffer (50 mM Tris-HCl pH 6.8, 100 
β-mercaptoethanol, 2% SDS, 1% Glycerol, 0.1% Bromophenol blue). Each 
sample was boiled for five minutes and sonicated. 30 μl were loaded in 10-
12% SDS-polyacrilamide gel (SDS-PAGE). The resolved proteins were 
blotted onto nitrocellulose transfer membrane (Schleicher & Schuell) at 100 
V for 1 hour. Membranes were blocked in TBS 0.1% Tween-20 (TBST) with 
5% dried milk for 1 hour at room temperature (R.T.) and then incubated 
O.N. with the primary antibody at the working diluition in TBST-milk.  
The following primary antibodies were used:  
• Home-made rabbit polyclonal anti-DJ-1 1:1000 
• Mouse monoclonal anti-Flag (Sigma) 1:4000 
• Mouse monoclonal anti-Hemoagglutinin (HA, kindly 
provided by Dr L. Collavin) 1:1000 
• Mouse monoclonal anti-Actin (Sigma) 1:5000 
• Rabbit Monoclonal anti-SUMO-2/3 (Zymed) 1:250 
The following secondary antibodies were used: 
• HRP conjugated goat anti-mouse antibody (DAKO) 1:1000 
• HRP conjugated goat anti-rabbit antibody (DAKO) 1:2000 
 
After washes with TBST (five minutes each), protein bands were detected 
by HRP/hydrogene peroxide catalyzed oxidation of luminol by an 
enhanced chemiluminescence system (ECL Westren blotting detection 
reagents, Amersham Biosciences) and autoradiography. 
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5.2 Immunoprecipitation 
 
To confirm DJ-1 SUMO-3ylation through immunoprecipitation, HEK293T 
transfection was performed as described. After 36-48 hours, cells were 
washed carefully with ice-cold PBS/NEM/IAA and lysed in RIPA buffer 
(150 mM NaCl, 50 mM Tris HCL pH 7.5, 0.5 % NP-40, 0.5% Deoxycholic 
Acid, 0.1% SDS) supplemented with Protease Inhibitors (Roche), NEM 
(Sigma) and IAA (Sigma). After centrifugation, the protein concentration 
of the supernatant was determined with Bradford method using a 
calibration curve built with standard amounts of Bovine Serum Albumine 
(BSA). Around 3-4 mg of proteins were subjected for each 
immunoprecipitation and each control. Immunoprecipitation of 
exogenous 2X-Flag-DJ-1 was carried out using 40 μl of Flag Resin (Sigma) 
for 2 hours at 4°C in rocking. For experiments in HEK293T, in Substantia 
Nigra and in Striatum, immunoprecipitations were carried out using the 
RIPA lysis buffer. 4 mg of protein were incubated with 2 μg of the 
immunoprecipitating antibodies (Rabbit IgG as control and anti DJ-1 
home made or anti SUMO-2/3). The incubation was carried out for 2 
hours followed by an incubation at 4°C with 40 μl of Sepharose A 
(Amersham) for 1 hour. Samples were washed four times with PBS or 
0.5% NP-40/PBS, the resin was pelleted and dried out with a syringe. 
Samples were further boiled with 20 μl of 2X Laemmli Buffer and 
subjected to SDS/PAGE on 10 % PAA gels. 
 
5.3 Isoelectrofocusing 
 
HEK293T cells were lysed in 7 M urea, 2 M Thiourea, 4% w/v CHAPS, 
1.2% v/v DeStreak Reagent, and 1% v/v IPG buffer 3–10 (Amersham 
Biosciences). IEF was performed on linear immobilized pH gradients (7  
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cm long/pH 4-7) according to the manufacturer’s instructions (Amersham 
Biosciences), loading 1 mg of total proteins, and using the paper bridge 
method and the IPGphor IEF System (Amersham Biosciences). At the end 
of IEF, the IPG strips were frozen (-80°C). Before running the second 
dimension, strips were equilibrated 2 x 15 min in 6 M urea, 50 mM 
Tris/HCl pH 8.8, 30% v/v glycerol, 2% w/v SDS and 1% (w/v) DTT (first 
equlilibration) or 2.5% (w/v) IAA (second equilibration). Second 
dimension electrophoresis was carried out on a 15% SDS polyacrylamide 
gel under constant current (20 mA for 60 min then 60 mA). Proteins were 
then transferred to nitrocellulose membrane and revealed using the 
enhanced chemiluminescence technique. 
 
6 IMMUNOFLUORESCENCE STAINING 
6.1 Immunocytochemistry 
 
Cells grown onto 13-mm poly-D-lysine-coated coverslips, once removed 
the medium and washed in PBS, were fixed in 4% Paraformaldehyde 
(PFA) at Room Temperature (R.T.) for 10 minutes. After fixation, cells 
were rinsed twice with PBS and first quenched with Glycine 0.1M/PBS for 
5’. Cells were permealized with 0.1% Triton X-100/PBS for 10 minutes and 
the nonspecific immunoreactivity were blocked for 30 minutes using 0.2% 
BSA (bovine serum albumine)-10% NGS (normal goat serum) at R.T. Both 
primary and secondary antibodies were incubated in 0.2% BSA/PBS.  
The following antibodies were used: 
• Mouse monoclonal anti-Flag (Sigma) 1: 2000, 1 hour 
• Mouse monoclonal anti-HA 1:1000, 1 hr  
• Home-made rabbit anti DJ-1 1:500, 1 hr 
• Rabbit anti-SUMO-2/3 (Zymed) 1:50, 3 hrs.  
After washes, cells were incubated with secondary antibodies. 
The following antibodies were used for 1 hour: 
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• AlexaFluor 488-conjugated goat anti-rabbit 
(Invitogen) 1:500  
• AlexaFluor594-conjugated goat anti-mouse 
(Invitrogen) 1:500   
 
DNA was stained with Hoechst33258 DAPI (Sigma) added during the 
incubation of the secondary antibody (1:2000). After washing in PBS and 
water, coverslips was mounted on slides using Vectashield mounting 
medium (Vector). 
 
6.2  Immunohistochemistry 
 
12 week-old mice were anesthetized and intracardially perfused with 4% 
PFA in PBS. Brains were dissected and postfixed for 1 hr at R.T. in 4% 
PFA. Serial coronal sections (40 μm) were cut at the vibratome, collected 
and preserved at 4ºC in 0,1% Sodium Azide.  
The slices were incubated for 1 hour in blocking solution (NGS 10%, BSA 
0,2%; Fish Gelatin 0, 1% in PBS) and then with the primary antibody, at 
the appropriate concentration, in a solution for antibody incubation.( BSA 
0, 2%, Fish Gelatin 0,1%, 0,1% Triton-X-100 in PBS) for 16-18 hours at R.T. 
The following primary antibodies were used: 
• Mouse monoclonal anti-Tyrosine Hydroxylase (TH 
Diarosin) 1:2000 
• Mouse monoclonal anti-NeuN (Chemicon) 1:300 
• Mouse monoclonal anti-GFAP (Sigma) 1:1000 
• Rabbit polyclonal anti-SUMO-2/3 (Zymed) 1:100 
After three washes with 0,2%BSA/PBS of 10 minutes each, the slices were 
incubated with the secondary antibody for 1hour at R.T. in the solution 
used for the primary antibody incubation.  
The following secondary antibody were used for 1 hour: 
 49 
• AlexaFluor 488-conjugated goat anti-rabbit 
(Invitogen) 1:500  
• AlexaFluor594-conjugated goat anti-mouse 
(Invitrogen) 1:500  
Nuclei were labeled with Hoechst33258, DAPI (Sigma) added 1:2000 
during the incubation of the secondary antibody. Slices were washed three 
times with PBS and mounted in vectashield mounting medium (Vector). 
Slides were examined using a Leica Confocal Microscope using 
independent excitation for all channels. Omission of primary antibody 
was used to evaluate non-specific fluorescence and in all cases gave no 
signal. 
 
7 IMMUNOAFFINITY PURIFICATION OF A 
POLYCLONAL ANTI-DJ-1 ANTIBODY RAISED IN 
RABBIT 
 
7.1 Purification of GST- DJ-1 fusion protein 
 
The full length cDNA of DJ-1 human protein was expressed in fusion with 
a glutathione-S-Transferase (GST) domain. E. Coli BL21 competent cells 
were transformed with pGEX-4T-1 vector containing the GST fusion 
protein. Before performing large scale purifications, protein expression 
was previously checked in the laboratory under different induction 
conditions to establish the optimal one. A single colony of transformed 
cells was inoculated O.N. at 37ºC in 20 mL of LB broth with Ampicilline 
(Amp). Then the culture was diluted into fresh LB in order to obtain a 
staring A600 of 0.2 and then it was grown to a final A600 of 0.8. The fusion 
protein was induced by adding IPTG to a final concentration of 1mM and 
growing the culture for an additional 2-3 hours at 30ºC. Then bacteria 
were pelleted at 6000 rpm at 4 ºC for 10 min and pellets were stored at 
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80ºC. The pellet was lysed in PBS supplemented with Protease Inhibitor 
(Roche) and sonicated on ice for 30’’and incubated on ice for 5 minutes.  
To separate the GST-fusion protein from all other proteins, the 
supernatant was incubated with glutathione resin (Glutathione Sepharose 
4B, Amersham Biosciences, 1mL for 100 mL of culture) for 2-4 hours at 4 
ºC. The GST fusion protein unbound to the Glutathione Sepharose and all 
other proteins were washed away with three washes in PBS. The GST 
protein was then eluited from the Glutathione Sepharose with 15 mM of 
reduced GST (GSH) in 50 mM Tris pH 8. The eluted GST fusion protein 
was quantified in SDS PAGE with standard amounts of BSA labeled with 
Coomassie staining. 
 
7.2 Immunization of rabbit with purified GST-DJ- 1 
 
The GST-DJ-1 purified protein was used for male rabbit immunization 
They were performed by Dr. Marco Stebel from the animal facility of the 
University of Trieste (Italy) with standard procedure. The protocol 
included 10 boosts with 100-150 μg of GST-DJ-1 fusion protein. Blood 
samples were collected either before immunization and after each single 
booster (1st-10 st bleads).  
 
7.3 Purification of the anti-DJ-1 antibody  
 
The GST-DJ-1 purified protein was used for coupling reaction and affinity 
purification of the antibody. 
GST and GST-DJ-1 were immobilized on CNBR-Activated Sepharose 4B. 
(Amersham Biosciences). 1 g of dried resin was weighed (1g freeze-dried 
powder gives about 3.5 mL final volume of medium) and suspended in 
1mL HCl. Several washes with 1mM HCl were made with a total volume 
of 200 mL. GST and GST-DJ-1 were dialyzed in Coupling Buffer (0.1 M 
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NaHCO3 pH 8.3, 0.5 M NaCl). About 2.5 mL of coupling solution and 5 mg 
of proteins either GST and GST-DJ-1 per mL of wet resin were used 
according to the manufacturer’s protocol. Coupling solution was 
incubated with the resin overnight rocking at 4° C. The excess of ligand 
was washed away with 5 medium volume of copling buffer. Unbound 
active groups were blocked with 0.1 M Tris HCl buffer pH 8 rocking for 2 
hours at R.T. The resin was washed with 3 cycles of alternating pH with 
5.0 medium volumes of each buffer. Each cycle consisted of a wash of 0.1 
M acetate pH 4 buffer 0.5 M NaCl followed by a wash of 0.1 M Tris HCl 
pH 8.0 buffer 0.5 M NaCl. The GST and GST-DJ-1 were transferred and 
packed onto two different columns. They were washed with buffer used to 
elute the antibodies in order to remove any antigen. Columns were 
washed with 10 volumes of 10 mM Tris HCl pH 7.5, then with 10 volumes 
of 10 mM Tris HCl ph 8.8 and several washes with 10 mM Tris HCl pH 7.5 
until reached pH 7.5. 5mL of rabbit serum were passed through the GST 
column in order to bind and to remove the GST-Antibodies. The flow 
through was collected and passed to the GST-DJ-1 column. Both the 
columns were washed with 20 volumes of 10 mM Tris-HCl pH 7.5 
containing 0.5 M NaCl. Anti-GST and anti-GST-DJ-1 were eluted by 100 
mM Glycine pH 2.5. Eluates were collected in tubes containing 1M Tris PH 
8.0 for equilibrating the antibody solution to pH 7.5. The pH of both 
columns was brought to pH 8.8 by washing with 10 mM Tris pH 8.8. The 
concentration of the antibodies were determined by measuring absorbance 
at 280 nm and using the following formula: Concentration (mg/mL)=A 
280/1.028. Columns were washed extensively with 10 mM Tris pH 7.5 
until the pH is reached and stored at 4°C with 0.02% sodium azide. The 
specificity of the affinity-purified anti-DJ-1 antibody was tested using the 
competition assay. 
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7.4 Competition Assay  
 
1, 3, 10 μg of purified GST-DJ-1 were incubated with the anti-DJ-1 
antibody for 2 hrs at 37ºC. The mixture was further used for western blot 
analysis or immunofluorescence.  
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 AIM OF THE PROJECT 
 
Homozygous deletions and missense mutations in the DJ-1 gene result 
into a EOARPD indicating that DJ-1 is involved in neuroprotection. 
Investigations of the biochemical and biological function of genes that 
cause inherited forms of Parkinson’s Disease are essential to elucidate the 
events that lead to dopaminergic neurodegeneration. 
To dissect the molecular events related to DJ-1 function, the laboratory of 
Prof. Stefano Gustincich has isolated a group of DJ-1 interactors from a 
human foetal brain cDNA library. Among others, Small Ubiquitin-like 
MOdifier 1 (SUMO-1), SUMO-activating enzyme (Uba2), and SUMO-
conjugating enzyme (Ubc9) were identified as DJ-1 interactors. DJ-1 has 
been recently reported to be SUMOylated by SUMO-1 at lysine-130 
(Shinbo et al., 2006) and to be involved in global protein SUMOylation 
(Zhong et al., 2006).  
Here I study the modification of DJ-1 by SUMO-2/3 in vivo and in vitro.  
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 RESULTS 
 
1 PRODUCTION AND PURIFICATION OF 
ANTI-DJ-1 ANTIBODY 
1.1 Purification of GST-DJ-1 fusion protein and 
rabbit immunization  
 
The full length DJ-1 was previously subcloned in our laboratory into a 
pGEX4-T1 vector and expressed in bacteria in fusion with GST. A large 
scale GST-DJ-1 was produced from 500 mL of induced BL21.  
The GST-DJ-1 purified protein was further used for the immunization of 
two rabbits. Immunizations and blood sampling were performed by 
Marco Stebel from the animal facility of the University of Trieste (Italy). 
Ten different boosts were collected.  
 
1.2 Purification of anti-DJ-1 antibody 
 
Two affinity columns were prepared, one coupled to the GST alone and  
the other to GST-DJ-1. GST and GST-DJ-1 proteins were previously 
purified from induced BL21 bacteria using the Glutation Sepharose Resin 
and dialyzed in Coupling buffer, as described in Material and Methods.  
The yield of purified GST and GST-DJ-1 protein was estimated in figure 8. 
The 7th  bleeding sera was first diluited 1:2 in equilibration buffer, 100 mM 
Tris HCl pH 7.5, then applied into the GST column to bind and eliminate 
the anti-GST antibody. The flow through was then loaded into the GST-
DJ-1 column in order to purify the anti-DJ-1 antibody. Specific antibodies 
were eluted from the column in acid conditions (Glycine 100 mM pH 2.5). 
The pH was brought to 8 by adding Tris HCl pH 8 and checking the pH 
with strips.  
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The concentration of the eluted antibody was determined through 
spectrophotometric measures and the presence of contaminants or 
degradation were checked by SDS-PAGE and further Blue-Coomassie 
staining (data not shown). 
 
   
Fig 8: A) Induction and purification of GST and the GST fusion protein DJ-1 and B) 
quantization towards standard amounts of BSA. 
 
1.3 DJ-1 is expressed in SH-SY5Y cells 
 
The purified serum was tested at different diluitions in Western Blotting 
experiments on SH-SY5Y cell lysates. Twenty μg of total lysate were 
loaded for each lane on SDS-PAGE and after blotting, membranes were 
incubated with 1:100, 1:200, 1:500, 1:1000 and 1:2000 diluitions of the 
purified anti DJ-1 antibody and with 1:100 of unpurified serum. A band 
corresponding to DJ-1 was detected at the expected molecular weight of 20 
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kDa. The anti-DJ-1 was subsequently used at 1: 1000 diluition. Results are 
shown in figure 9A. 
Competition experiments were also performed to prove the specificity of 
the detected band. Briefly, the anti-DJ-1 antibody was incubated with 0, 1 
and 3 μg of antigen (GST-DJ-1) for 2 hours at 37ºC before the Western blot 
detection. The 24 kDa band detection was abolished completely by using 
1μg of antigen (GST-DJ-1) as indicated in figure 9B. 
 
 
Fig 9: DJ-1 is expressed in SH-SY5Y cells. A) Different diluitions of the anti-DJ-1 
antibody purified from 7th serum on 20 μg of SH-SY5Y cell extracts. B) Competition 
experiments with 0, 1 and 3 μg of GST-DJ-1 respectively to lane 1, 2, 3. 
 
Similar experiments were performed in immunofluorescence. The purified 
antibody was incubated at the working solution 1:500 with 1 μg of GST-
DJ-1 and the cellular localization was further analized at the confocal 
microscope. The detection of the DJ-1 cellular localization is abrogated in 
competition experiments (Figure 10). 
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It has been reported that DJ-1 is localized in various subcellular 
compartments of the cells, mainly in the cytoplasm but also in the nucleus 
and in the mitochondria (Bonifati at al., 2003). 
This anti-DJ-1 antibody detected the cytoplasmic and the nuclear 
localization, while specific mitochondrial localization was not observed 
after the PFA fixation.  
 
 
Fig 10: A) nuclear and cytoplasmic DJ-1 localization on SH-SY5Y B) competition 
experiment using 1 μg of GST-DJ-1 with the working diluition of 1:500 of the home-
made anti-DJ-1 indicating the specificity of cellular localization. Scale bar 45 μm. 
 
2 DJ-1 LOCALIZATION IN MOUSE BRAIN 
 
This anti-DJ-1 antibody was used to analyze the localization of 
endogenous DJ-1 in mouse brain, with special enphasis to the Substantia 
Nigra, brain region in which dopaminergic cells degenerate in Parkinson’s 
Disease. Mouse brain coronal slices stained with anti-DJ-1 antibody 
presented two different cellular staining: a marked astrocytic expression 
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and a neuronal labelling. To demonstrate the expression of DJ-1 in both 
type of cells, double Immunofluorescence experiments were performed. 
As shown in figure 11 DJ-1 co-localizes with glial cells stained with anti-
GFAP (Glial Fibrillary Acidic Protein) antibody, which is used as a glial 
marker. It worth noting that in glial cells the localization of DJ-1 is both 
nuclear and cytosolic. Other GFAP-negative cells, assumed to be neurons, 
displayed a predominant cytoplasmic localization.  
Further investigations confirmed the DJ-1 is expressed in dopaminergic 
cells, by using an antibody specific for these neurons, the anti-TH 
(Tyrosine Hydroxylase). 
As shown in figure 12 the double Immunofluorescence using the anti DJ-1 
and anti-TH antibodies indicated the expression of DJ-1 in dopaminergic 
cells. This was confirmed by the cytofluorogram (figure 13) obtained by 
plotting for each point of the cell the fluorescence green on the x axis and 
the fluorescence red on the y axis. Co-localization is indicated from the 
yellow points in the centre of this graph. 
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Figure 11: Immunocytochemistry of midbrain sections with anti-GFAP and anti-DJ-1 
antibodies. Scale bar 25 μm. 
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Figure 12: Immunocytochemistry of midbrain sections with anti-TH and anti-DJ-1 
antibodies. Scale bar 15 μm. 
 
 
Figure 13: Cytofluorogram analysis of figure 12 stained with anti-TH and anti-DJ-1 
antibodies confirmed the DJ-1 localization in dopaminergic neurons. 
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3 CONFIRMING THE YEAST TWO HYBRID 
SCREENING 
3.1 DJ-1 interacts with Ubc9 
 
Ubc9 is the only SUMO-conjugating enzyme in yeast and in vertebrates. It 
doesn’t discriminate between SUMO-1, SUMO-2, SUMO-3. To confirm the 
data from the Yeast Two Hybrid Screening, the interaction between 
endogenous DJ-1 and the transfected Ubc9 was analyzed in HEK293T cell 
by co-immunoprecipitation assay.  
HEK293T cells were transfected with pCDNA3-HA-Ubc9 (kindly 
provided by Dr. Licio Collavin) and, after 48 hours, cells were lysed and 
protein extracts were subjected to immunoprecipitation using the home-
made polyclonal anti-DJ-1 antibody. The western blot was revealed using 
an anti-HA antibody. As shown in figure 14, the overexpressed HA-Ubc9 
co-immunoprecipitates with the endogenous DJ-1. No background was 
observed in the control immunoprecipitation using anti-Rabbit IgG. The 
interaction between endogenous DJ-1 and ectopic Ubc9 was confirmed in 
vitro in mammalian cell lines. 
 
 
Fig 14: Endogenous DJ-1 co-immunoprecipitate with transfected HA-Ubc-9. Lane 1, 
total input protein (20 μg); Lane 2, immunoprecipitation with anti-DJ-1 antibody; Lane 
3, immunoprecipitation with Rabbit IgG. 
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4 DJ-1 IS SUMO-2/3YLATED 
4.1 Endogenous DJ-1 is covalently modified by 
endogenous SUMO-2/3 in HEK293T 
 
To determine whether DJ-1 is modified by SUMO-2/3 in addition to 
SUMO-1 (Shinbo et al., 2004), immunoprecipitation experiments were 
performed from HEK293T cells using a polyclonal antibody anti-SUMO 
2/3 (Zymed), the polyclonal antibody anti-DJ-1 home-made and affinity 
purified and a Rabbit IgG as a negative control. Since SUMO-2 and 
SUMO-3 share 95% homology, the available commercial antibodies don’t 
discriminate between these two isoforms.  
Immunoprecipitations were loaded into a 10% PAA gel and the slower 
migrating DJ-1 form was recognized probing the western blot with the 
anti-DJ-1 antibody. The apparent molecular weight of the 
immunoprecipitated DJ-1 is consistent with the addition of a single 
SUMO-2/3 molecule, as shown in figure 15. The membrane stripped and 
incubated with the anti-SUMO-2/3 antibody detected the same bands 
(data not shown). This experiment suggests that endogenous DJ-1 is 
modified by endogenous SUMO -2/3 in mammalian cell lines. 
 
Figura 15: Immunoprecipitation of endogenous DJ-1 modified by endogenous SUMO-
2/3 in HEK293T. 
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4.2 Colocalization of DJ-1 and SUMO-2/3 in SH-
SY5Y 
 
SUMO-2/3 (Su et al., 2002) are mostly localized in the nucleus. Because of 
the high degree of homology between SUMO-2/3, these proteins are 
virtually identical and share similar protein distribution. 
Immunofluorecence experiments were performed on SH-SY5Y to 
investigate the cellular localization of SUMO-2/3. DJ-1 was detected using 
a monoclonal antibody (Zymed) and SUMO-2/3 a polyclonal one 
(Zymed). Anti-mouse 488 was used to detect the DJ-1 localization and 
anti-rabbit 594 for SUMO-2/3. This immunofluorescence experiment 
indicated that a partial co-localization between DJ-1 and SUMO-2/3 
occurs in the nucleus (figure 16). 
 
Figure 16: Immunofluorescence of endogenous SUMO-2/3 and DJ-1 and their nuclear 
co-localization in SH-SY5Y.Scale bar 15 μm. 
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4.3 DJ-1 is modified by SUMO-2/3 in Striatum and 
Substantia Nigra 
 
In order to validate the DJ-1 modification by SUMO-2/3 and its 
importance in Parkinson’s Disease, Immunoprecipitation experiments 
were performed from Striatum and Substantia Nigra total protein extracts. 
These specific mouse brain regions were chosen since PD is characterized 
by the degeneration of nigrostriatal dopaminergic pathway. 
Endogenous DJ-1 was immunoprecipitated using the home-made 
polyclonal antibody. As control, Rabbit IgG was used to 
immunoprecipitate the same amount of protein. Immunoprecipitations 
and inputs (100 μg) were subsequently loaded into a 10% PAA gels and 
western blots were revealed with both the anti-DJ-1 and the anti-SUMO-
2/3 antibodies.  
These experiments confirmed that DJ-1 is subjected to a covalent post 
translational modification in vivo, which is responsible of the detection of a 
DJ-1 species of ∼15 kDa higher molecular weight. Revealing the western 
blot with SUMO-2/3 confirmed that the modification is due specifically to 
the addition of a single SUMO-2/3 mojety.  
It is worth noting that the covalent post translational modification of DJ-1 
by SUMO-2/3 occurs in both striatum and substantia nigra with the same 
efficiency.  
Results are shown in figure 17 and blots are representative of at least three 
separate experiments. 
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Figure 17: A) DJ-1 is SUMO-2/3ylated in vivo in Substantia Nigra and in B) striatum 
isolated from mouse brain.  In the short exposure inputs of free SUMO-2/3 and DJ-1 
were detected; the long exposure was essential to detect the immunoprecipitated 
fraction of SUMO-2/3ylated DJ-1. 
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4.4 Confirmation of DJ-1 modification by SUMO-2/3 
 
DJ-1 SUMOylation by SUMO-2/3 was then monitored using additional 
techniques in order to provide a definitive evidence for DJ-1 sumoylation.  
On this purpose, two different approaches have been used.  
 
1. The post translational modification of DJ-1 by covalent attachment 
of SUMO-2/3 was studied using isoelectrofocusing on endogenous 
protein extracts from HEK293T. 
 
2. Transient co-transfection experiments of DJ-1 and of the SUMO-
2/3 conjugation pathway  
 
4.4.1 Isoelectrofocusing. 
 
Two-dimensional gel electrophoresis experiments were performed on 
HEK293T in collaboration with Prof. G. Manfioletti and Dr. R. Sgarra from 
University of Trieste. 
Protein extracts were prepared as described in “material and methods” 
and 1 mg of protein was resolved by isoelectric focusing on 7-cm 
immobilized pH gradient strip (4-7). Second dimensional separation was 
performed by electrophoresis on 15% SDS-PAGE. Then western blots were 
analyzed with the home-made anti-DJ-1 antibody.  
It was previously demonstrated that DJ-1 exists as a homodimeric protein 
that migrates on SDS gels as a 20 kDa monomer because of denaturation 
by SDS (Olzmann et al., 2004; Rizzu et al., 2004). Furthermore, immunoblot 
analysis revealed that at least three different distinct isoforms of DJ-1 
monomer exist. They have the same apparent molecular weight of 20 kDa 
but different isoelectric points (6.1; 6.4; 6.6). In our analyses we were able 
to detect DJ-1 at the expected molecular weight. IEF allowed us to 
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evidence two maily forms (poorly focalized due to overload effects): one 
at ∼ pI 6.0 and the other at ∼ pI 6.6. These results were in good agreement 
with both the predicted values of 20 kDa/pI 6.33 for the DJ-1 monomer 
(calculated by www.expasy.org) and the data present in literature (Taira et 
al., 2004; Choi et al., 2006).  
Two gels were loaded independently, one was revealed with the purified 
anti-DJ-1 antibody, the other one with the anti-SUMO-2/3 antibody. 
In addition to the monomeric forms of DJ-1, an immunoreactive spot at 
about 35 kDa and at a more acidic pI (5.8) form was observed with the 
anti-DJ-1 antibody. This spot perfectly matched with that one recognized 
by the anti-SUMO-2/3 antibody, indicating clearly that endogenous DJ-1 
is SUMO-2/3ylated in HEK293T. 
This result supported the theoretical analysis done with the in silico 
program on www.expasy.org that allows to determine the pI/mw. 
Human SUMO-2/3 have a theoretical pI of 5.34, instead human SUMO-1 a 
theoretical pI of 5.19. The addition of one moiety of SUMO-2/3 leads to a 
shift both in the pI with a consequent acidification and in the DJ-1 
molecular weight as previously demonstrated. Depending on the 
algorithm used to perform in silico analysis, the predicted shift in the pI 
upon SUMO-2/3 DJ-1 modification is between 5.47-5.85.  
The spot detected in these experiments and confirmed to be DJ-1-modified 
by SUMO-2/3 displayed a pI shift according to the in silico prediction 
analysis.  
Results are shown in figure 18 and are representative of at least three 
separate experiments. 
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Figure 18: Bidimensional gel analysis of whole protein extracts from HEK293T. Gels 
were revealed with anti-DJ-1 and anti-SUMO-2/3 antibodies. A modified form of DJ-1 
with a shift in the molecular weight and in the pI was detected. The same spot was 
recognized also by the anti-SUMO-2/3 antibody, indicating that endogenous DJ-1 is 
modified by SUMO-2/3 in HEK293T. 
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4.4.2 Cloning and characterization of HA-SUMO-2 
and HA-SUMO-3 conjugable and unconjugable. 
 
To further confirm the modification of DJ-1 by SUMO-2/3, in vitro 
experiments were performed.  
First, constructs encoding tagged SUMO-2 and SUMO-3 were generated 
by subcloning the entire SUMO-2 wild type cDNA and SUMO-3 wild type 
cDNA into a pcDNA3-HA vector. Both cDNAs (kindly provided by Prof. 
Giannino Del Sal, University of Trieste, Italy) were fused to the HA 
epitope at the N-terminal, maintaining the C-terminal accessible for its 
processing and the consequent protein activation with the exposition of 
the di-Glycine motif. 
The unconjugable form of SUMO-2 and SUMO-3 were generated by PCR-
Site Directed Mutagenesis using specific designed primers that could 
convert the di- Glycine motif at the C-terminal into a di-Alanine motif. The 
cDNA obtained was consequently subcloned into the same pcDNA3-HA 
vector. In the figure 19 the procedure is briefly summarized. 
 
 
Figure 19: Schematic representation of PCR Site-Directed Mutagenesis on SUMO-2 
and SUMO-3 in order to convert the di-Gly motif into di-Ala motif creating the 
unconjugable form of the SUMOs proteins. 
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Expressions of wild type SUMO-2 and SUMO-3 fusion proteins and of 
their unconjugable forms were tested in transient transfection experiments 
followed by both Western blot analysis and Immunofluorescence using 
the monoclonal antibody anti-HA. 
In figure 20 the expression was tested by western blot analysis in a 15% 
PAA gel of both conjugable and unconjugable forms of HA-SUMO-2 and 
HA-SUMO-3. The fusion proteins are detected at the predicted molecular 
weight, 20 kDa. Interestingly, for HA-SUMO-3, two bands were detected. 
It was deduced that the slower migrating form is the inactive protein, 
while the faster migrating form is the activated one. The activation leads 
to the exposition of a di-Gly motif due to the cleavage of a peptide of 12 
amino acid. 
 
 
Figure 20: Expression analysis of both HA-SUMO-2 and HA-SUMO-3 in both 
conjugable and unconjugable forms. The western blot was revealed using the anti-HA 
antibody. 
. 
According to this result, the inactivated HA-SUMO-3 runs at the same 
molecular weight of the unconjugable HA-SUMO-3.  
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The SUMO-2 activated/inactivated proteins cannot be appreciated 
because only 2 amino acids are released after its activation.  
The expression the HA-SUMO-2 and HA-SUMO-3 fusion proteins in both 
conjugable and unconjugable forms were also tested in 
immunofluorescence, as shown in figure 21A and figure 21B respectively, 
using the anti-HA antibody. 
The predominant cellular localization of HA-SUMO-2 in the conjugable 
form was nuclear, while the unconjugable form presented a marked 
cytoplasmic localization. Similar results were obtained transfecting the 
conjugable HA-SUMO-3 in HEK293T: both nuclear and also cytoplasmic 
localization were detectable. The corresponding unconjugable form 
displayed a cellular localization similar to the wild type form. 
 
 
Figure 21A) Immunofluorescence on HEK293T after transient transfection with HA-
SUMO-2 in both conjugable and unconjugable forms. The cellular localization was 
detected using an anti-HA antibody. Scale bar 15 μm. 
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Fig 21B) Immunofluorescence on HEK293T after transient transfection with 
conjugable and unconjugable HA-SUMO-3. The cellular localization was detected 
using anti-HA antibody. Scale bar 15 μm. 
 
4.4.3 Validation of the conjugable and unconjugable 
forms of HA-SUMO-2 and HA-SUMO-3 proteins 
 
The abilility of HA-SUMO-2/HA-SUMO-3 wild type to be efficiently 
conjugated to endogenous cellular proteins was tested in transient co-
transfection experiments with the E2-conjugating enzyme, HA-Ubc9. 
Western blotting experiments were revealed using the antibody anti-HA. 
Consistent with previous reports (Gostissa et al., 1999), a high molecular 
weight smear was observed. This result indicates that several endogenous 
cellular proteins could be covalently modified by conjugation to the 
transfected tagged SUMO-2 (figure 22A) and SUMO-3 (figure 23A) in the 
presence of HA-Ubc9.  
These unconjugable forms were also validated through western blotting 
analysis: when these cDNAs were transfected in the presence of the E2-
conjugating enzyme, the conjugation of exogenous unconjugable HA- 
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SUMO-2/3 protein to endogenous cellular protein was totally abrogated 
(figure 22 and 23 B). 
HA-UBC 9
+ +
+ +-
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55 kDa
40 kDa
33 kDa
+ +-
+ +-
A B
 
Figure 22: Sumoylation analysis of A) HA-SUMO-2 wild type and B) HA-SUMO-2 
unconjugable in the presence of HA-Ubc9. The western blot was revealed using an 
anti-HA antibody. 
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Figure 23: Sumolation analysis of A) HA-SUMO-3 wild type and B) HA-SUMO-3 
unconjugable in the presence of HA-Ubc9. The western blot was revealed using an 
anti-HA antibody. 
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These results indicated that the use of unconjugable forms of HA-SUMO-2 
and HA-SUMO-3 are good internal controls to demonstrate that a protein 
of interest is sumoylated. 
Specific experiments were performed with tagged DJ-1 to demonstrate its 
covalent post translational modification in transient co-transfection 
experiments. 
 
4.5 Confirming the post translational modification 
of DJ-1 by covalent attachment of SUMO-2/3 using 
Western Blot analysis 
 
To confirm that DJ-1 can be modified by SUMO-2 and SUMO-3, DJ-1 
sumoylation was analyzed in transient transfections. HEK293T were 
transfected with equimolar amounts of the following plasmids: 2X-Flag-
DJ-1, HA-SUMO-2/3 in both conjugable and unconjugable forms and HA-
Ubc9.  
The following transfections were performed: 2X-Flag-DJ-1; 2X Flag DJ-1 + 
HA-Ubc9; 2X-Flag-DJ-1 + HA-Ubc9 + HA-SUMO-2/3 conjugable; 2X Flag 
DJ-1 + HA-Ubc9 + HA-SUMO-2/3 unconjugable; 2X-Flag-DJ-1 + HA-
SUMO-2/3 conjugable and, finally, HA-Ubc9 + HA-SUMO-2/3 
conjugable. 
Thirty-six hours after transfection, cells were lysed in hot SDS sample 
buffer and analyzed by Western blotting using the anti-Flag, anti-DJ-1 
(data not shown) and anti-HA antibodies. Only when the 2X-Flag-DJ-1 
was co-expressed with HA-SUMO-2/3 in the conjugable form and HA-
Ubc9, a more slowly migrating band was visible, as shown in figure 24. 
The molecular weight (~ 42 kDa) was consistent with a form of transfected 
2X Flag DJ-1 covalently modified by a single moiety of HA-SUMO-2 or 
HA-SUMO-3. The DJ-1 modification was observed only when co-
transfected with the HA-Ubc9. 
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The specificity of the modification was confirmed by the transfection of 
unconjugable HA-SUMO-2 and HA-SUMO-3. No shifted DJ-1 cross-
reactive bands were observed.  
Anti-HA antibody detected a ladder of bands representing the HA-
SUMO-2/3 conjugated cellular proteins in cells transfected with HA-
SUMO-2/3 and HA-Ubc9.  
Figure 24 shows representative results of at least three separate 
experiments for each blot and demonstrates that SUMO-2/3 proteins 
efficiently modify DJ-1 in transient transfections. .   
 
 
Figure 24: Sumoylation analysis of DJ-1 in transient transfection with HA-SUMO 2 
(left panel) and HA-SUMO 3 (right panel). Westen blotting were revealed with anti-
Flag to detect transfected DJ-1 and with anti-HA to detect the SUMO-2/3 protein 
conjugation. The band at 42 kDa detected with anti Flag was also recognized by anti-
DJ-1 (data not shown). 
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Furthermore, since SUMO-2 and SUMO-3 presents 98% identity in their 
activated form (except for two amino acid), only HA-SUMO-3 was used 
for this study in transient transfection. The same result was obtained with 
6Xmyc DJ-1; the use of different tags didn’t affect the reproducibility of 
DJ-1 SUMO-2/3ylation after transient transfection, as shown in figure 25. 
 
 
Figure 25: SUMOylation analysis of 6X-myc-DJ-1. The tag doesn’t affect the 
reproducibility of the result. 
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4.6 Confirming the post translational modification 
of DJ-1 by covalent attachment of SUMO-2/3 using 
immunoprecipitation 
 
Immunoprecipitation experiments were performed to confirm that the 
band detected at 42 kDa was DJ-1 sumoylated by SUMO-2/3. HEK293T 
were transiently trasfected with 2x-Flag-DJ-1 alone; 2x-Flag-DJ-1 + HA-
SUMO-3 conjugable and HA-Ubc9; 2x-Flag-DJ-1 + HA-SUMO-3 
unconjugable and HA-Ubc9. Since SUMO-2 and SUMO-3 are identical in 
their processed form, all the experiments were performed with HA-
SUMO-3.  
Thirty-six hours post-transfection, cells were lysed and DJ-1 was 
immunoprecipitated using a Flag-Resin and analyzed by western blotting 
with an anti-Flag antibody. As shown in figure 26 the band at 42 kDa was 
specifically immunoprecipitated by the resin and recognized by the 
antibody, indicating that the transfected DJ-1 is covalently modified only 
when the conjugable form of HA-SUMO-3 is co-transfected.  
To further demonstrate that the modification was due to SUMO-3ylation, 
the membrane was stripped and probed with anti-HA. The antibody 
recognized a band of the same size. 
The same membrane was re-incubated after stripping with the affinity 
purified anti-DJ-1: as expected, the band at 42 kDa was recognized 
confirming that transfected DJ-1 is modified by exogenous SUMO-3 in the 
presence of Ubc9. 
Figure 26 shows representative results of at least three separate 
experiments.   
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Figure 26: Confirmation of DJ-1 modification by SUMO-3. Whole protein extract from 
HEK293T transfected with 2X-Flag-DJ-1; 2X-Flag-DJ-1, HA-SUMO-3 and HA-Ubc9; 2X-
Flag-DJ-1, HA-SUMO-3 unconjugable and HA-Ubc9 was subjected to 
immunoprecipitation with Flag Resin. Western Blot was revealed with anti-Flag, anti-
HA and anti-DJ-1 antibody after sequential stripping.
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4.7 Identification of the Sumoylated Lysines in DJ-1 
4.7.1 In silico SUMOylation prediction programs 
 
SUMO attachment to target proteins occurs at specific lysine residue, 
which are in most cases embedded in the consensus sequence ψ-K-X-E (ψ 
is a hydrophobic amino acid) (Johnson S.M.,2004) or ψ-K-X-E/D(Melchior 
F., 2003) as described in the Introduction. 
To identify the lysine that is involved in DJ-1 modification, a sequence 
analysis by SUMO plot was performed (available at www.expasy.org) 
This program is a tool for in silico sumoylation sites prediction. It showed 
that Lys 182 lies within the canonical sequence ψ-K-X-E indicating an high 
probability to be a SUMO acceptor. The same program indicated Lysines 
41, 62, 63 and 148 with a low probability motives.  
The accumulating experimental data show that about ~23% of real 
sumoylation sites don't follow the standard motif, leading to both false 
positive and false negative sumoylation site predictions. These unexpected 
features introduce difficulties into the sumoylation analysis.  
Interestingly, it was recently published that Lys 130 is the acceptor for 
SUMO-1 modification (Shinbo et al., 2005).  
A new program, SUMOsp, was recently developed. 239 experimentally 
verified sumoylation sites were considered for the data set. The final 
prediction system showed satisfying sensitivity and specificity (Xue et al., 
2006). This program can be freely accessed from: http: 
//bioinformatics.Icd-ustc.org/sumosp/. 
The SUMOsp program indicates that the most probable Lys in DJ-1 is 62, 
(performing an analysis with an high cut off), then Lysines 4 and 182 and 
Lysines 4, 32, 62, 89, 93, 175, 182 and 187. These in silico analysis are 
summarized in figure 27. 
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Figure 27: Schematic representation of the results for in silico prediction analysis 
programs used to determine potential lysines.  
 
4.7.2 Characterization of DJ-1 lysines mutants 
 
To verify which residues are in vivo acceptors of SUMO-3, point mutations 
were introduced into the 2X-Flag-DJ-1 in order to convert Lys into Arg 
without altering the total charge of the protein and, consequently, it’s 
structure.  
Lysines 62/63 and Lysines 89/93 were mutated together according to the 
protocol followed in section “Material and Methods”. 
The following clones have been created using the strategy of the PCR Site- 
Directed Mutagenesis: 
 
• 2X-Flag-DJ-1 Lys4Arg (DJ-1K4R) 
• 2X-Flag-DJ-1 Lys12Arg (DJ-1K21R) 
• 2X-Flag-DJ-1 Lys32Arg (DJ-1K32R) 
• 2X-Flag-DJ-1 Lys41Arg (DJ-1K41R) 
• 2X-Flag-DJ-1 Lys62/63Arg (DJ-1K62/63R) 
• 2X-Flag-DJ-1 Lys89/93Arg (DJ-1K89/93R) 
  81
• 2X-Flag-DJ-1 Lys99Arg (DJ-1K99R) 
• 2X-Flag-DJ-1 Lys122Arg (DJ-1K122R) 
• 2X-Flag-DJ-1 Lys130Arg (DJ-1K130R) 
• 2X-Flag-DJ-1 Lys132Arg (DJ-1K132R) 
• 2X-Flag-DJ-1 Lys148Arg (DJ-1K148R) 
• 2X-Flag-DJ-1 Lys175Arg (DJ-1K175R) 
• 2X-Flag DJ-1 Lys182Arg (DJ-1K182R) 
• 2X-Flag-DJ-1 Lys187Arg (DJ-1K187R)  
 
These clones were first tested in transient transfections in both Western 
Blot (figure 28A) and Immunofluorescence (figure 28B) using the anti-
Flag antibody. As expected, all DJ-1 clones displayed the same rate of 
expression in transient transfection and they shared the same cytoplamic 
and nuclear localization as the wild type form of 2X-Flag-DJ-1. Figure 28A 
and figure 28B show representative results of at least three separate 
experiments.   
 
Fig 28: DJ-1 Lysines mutant expression by Western blot with the anti-Flag antibody. 
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Fig 28B: DJ-1 Lysines mutant expression by Immunofluorescence with the anti-Flag 
antibody. Scale bar 45 μm. 
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4.8 SUMOylation analysis of DJ-1 lysines mutants 
 
To investigated which lysines are sites of SUMO-3 conjugation, HEK293T 
were co-transfected with HA-SUMO-3 in the conjugable form, HA-Ubc9 
and wild type 2X-Flag-DJ-1, as well the 2X-Flag-DJ-1 in which Lys were 
changed into Arg. As a negative control, co-trasfection of 2X-Flag-DJ-1 
wild type, HA-Ubc9 and HA-SUMO-3 GG91/92AA was performed. 
Cells were lysed directly into hot 2X Laemmly Buffer and proteins were 
subjected to SDS-Page and Western Blot analysis using the anti-Flag 
antibody.  
As shown in figure 29 none of the DJ-1 single/double Lysines mutants 
abrogated the DJ-1 SUMO-3ylation, indicating that more than one lysine 
can be  sumoylated alternatively by SUMO-3. 
 The same gel was stripped and probed with anti-HA antibody to evaluate 
the transfection efficiency of the HA-SUMO-3 conjugation in the presence 
of the E2-conjugating enzyme HA-Ubc9. 
Since DJ-1 is modified by SUMO-1 on Lys 130 (Shinbo et al., 2005), the 
SUMO-3 modification on DJ-1 occurs on different Lys respect to SUMO-1 
and more than one Lys can be modified alternatively by SUMO-3. 
It is also worth noting that in the case of DJ-1 the in silico prediction 
analyses were insufficient per se to identify the target Lys for both SUMO-1 
and SUMO-3. 
Figure 29 shows representative results of separate experiments for each 
Lys/Arg mutant. 
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Figure 29: Sumoylation analysis of DJ-1 Lys mutants. None of the Lys X Arg was able 
to abrogate the sumoylation indicating that more than one Lys can be sumoylated 
alternatively. 
 
The in silico mapping, using both SUMO plot and SUMOsp server, 
indicated that Lys 182 and Lys 62 were the most probable lysines involved 
in sumoylation. Analysis of lysine sumoylation within DJ-1 revealed that 
none of single and double lysines mutations significantly affected the DJ-1 
SUMO-3 conjugation. Since the combined approach of Single Lysines PCR 
Site-Directed Mutagenesis and in silico prediction was unsuccessful, 
multiple Lysines were changed into Arginines in the same polypeptide.  
To chose among the different combinations we took into account the in 
silico prediction programs and the conservation of Lysines during 
evolution.  
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Two different clones were created, the 2X-Flag-Lys 62/63/130/182-Arg 
DJ-1 and (DJ-1 4M) the 2X-Flag-Lys 4/62/63/130/182/187-Arg DJ-1 (DJ-1 
6M): the Lys 130 was considered because it’s known to be acceptor for 
SUMO-1 (Shinbo et al., 2005); Lysines 62/63 are acceptors by SUMO plot; 
Lys 182 is the most probable amino acid according to SUMO plot; Lys 62 is 
the potential SUMO modification site for SUMO sp with an high cut off 
analysis; Lys 4 and Lys 187 are predicted to be SUMO acceptor with a 
middle cut. These last two amino acids are also highly conserved during 
evolution.  
Preliminary experiments tested the level of expression of these DJ-1 
mutants respect to the DJ-1 wild type and their cellular localization. No 
significative changes were appreciated in both western blot analysis 
(figure 30A) and immunofluorescence using the anti-Flag antibody (figure 
30B). 
 
Figure 30A: Analysis expression of DJ-1 4M (Lys 62/63/130/182 Arg) and DJ-1 6M (Lys 
4/62/63/130/182/187Arg) respect to the wild type in western blot using anti-Flag 
antibody. 
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Figure 30B: Analysis expression of DJ-1 4M (Lys 62/63/130/182 Arg) and DJ-1 6M (Lys 
4/62/63/130/182/187Arg) respect to the wild type in immunofluorescence using anti-
Flag antibody. Scale bar 10 μm. 
 
Subsequently, HEK293T were transfected with the DJ-1 multiple mutants, 
HA-SUMO-3 and HA-Ubc9 and total cellular proteins were subjected to 
SDS-PAGE and blotting analysis with the anti-Flag antibody in order to 
analyze the sumoylation pattern. Notably, the multiple DJ-1 mutants still 
retained sumoylation indicating that multiple Lys residues are not SUMO-
3 acceptors within DJ-1 and excluding again that the Lys 130 is the major 
sumoylation site for SUMO-3.  
Result shown in figure 31 are representative of at least three different 
experiments.  
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Figure 31: Sumoylation analysis of DJ-1 4M and DJ-1 6M respect to the wild type with 
anti-Flag and anti-HA antibody. 
 
In collaboration with Prof. P. Carloni and Dr A. Jezierska, a computational 
approach was addressed to identify the lysines responsible of SUMO-
3ylation. Docking and molecular dynamics (MD) calculations were 
runned between DJ-1 wild type and SUMO-3. The crystal structure of 
SUMO-3 was still not resolved but was deduced from that of SUMO-2. 
MD calculations pointed to a role of Lys 130 and Lys 132. In order to 
investigate whether this new combination could affect sumoylation, a new 
DJ-1 mutant was created by PCR Site-Directed Mutagenesis. The 
expression was tested in transient transfection in both western blot (figure 
32A) and immunofluorescence (figure 32B) analyses. Unfortunately, DJ-1 
Lys 130/132 Arg retained the SUMOylation status. Results repeated in 
triplicate are shown in figure 33.  
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Figure 32A: Expression analysis of DJ-1 Lys 130/132 Arg respect to the wild type 
protein with anti-Flag antibody. 
 
 
 
Figure 32B: Subcellular localization analysis of DJ-1 Lys 130/132R with anti-Flag 
antibody. Scale bar 10 μm. 
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Figure 33: Sumoylation analysis of DJ-1 Lys 130/132 Arg respect to the wild type 
protein with anti-Flag and anti-HA antibodies. 
 
4.9 SUMOylation analysis of DJ-1 pathological 
mutants 
 
SUMO-3ylation was analyzed for some DJ-1 mutant proteins associated to 
familiar form of PD. A particular attention was focused on the DJ-1 
Leu166Pro (L166P) and DJ-1Met26Iso (M26I). 
HEK293T were transfected with 2X-Flag-DJ-1-Leu166Pro or 2X-Flag-DJ-1 
Met26Iso in the presence of the HA-Ubc9 and of the conjugable form of 
HA-SUMO-3. As negative control, cells were transfected in the presence of 
the HA-SUMO-3 GG91/92AA instead of the wild type protein. 
As shown in figure 34, co-transfection of the mutant 2X-Flag-DJ-1-
Leu166Pro, HA-Ubc9 and HA-SUMO-3 in the conjugable form led to the 
detection of hyper-sumoylated form of DJ-1-LeuL166Pro respect to the 
wild type DJ-1 protein. A stronger signal was detected for the band at 42 
kDa while a band at 60 kDa band was also visible.  
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These results indicated that the amount of 2X-Flag-DJ-1-Leu166Pro 
covalently modified by SUMO-3 is higher respect to the wild type protein 
and that or it is polysumoylated by a poly-SUMO chain or multi-
sumoylated on different Lysines. The nature of the modification is still not 
known and further experiments are required to investigate this aspect. 
 The 2X-Flag-DJ-1 Met26Iso displayed a modification comparable to the 
2X-Flag DJ-1 wild type protein (figure 34). 
Results are representative of at least three separate experiments. 
 
 
Figure 34: SUMOylation analysis of DJ-1 pathological mutants with anti-Flag and anti-
HA antibodies. The DJ-1-Leu 166Pro is Hypersumoylated respect to the wild type 
protein and DJ-1-Met26Iso
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4.10 SUMOylation analysis of DJ-1 functional 
mutants 
 
SUMO-3ylation was analyzed for some functional DJ-1 mutants, which 
carried the point mutation Cys53Ala (C53A) and Cys106Ala (C106A). As 
described in the introduction, several studies indicated that reactive 
Cysteines play a critical role in the function and/or regulation of DJ-1 
activity, which is consequently abrogated by mutagenizing Cys to Ala.  
HEK293T were transfected with 2X-Flag-DJ-1 Cys53Ala or 2X-Flag-DJ-1 
Cys106Ala in the presence of the E2-conjugating enzyme, HA-Ubc9, and 
the conjugable form of HA-SUMO-3. As negative control, cells were 
transfected in the presence of the unconjugable HA-SUMO-3. 
As shown in figure 35, DJ-1-Cys53Ala and Cys106Ala displayed a 
sumoylation comparable to the wild type form. Results are representative 
of at least three separate experiments. 
 
Figure 35: SUMOylation analysis of DJ-1 functional mutants with anti-Flag and anti-
HA antibodies.  
  93
5 MAY OXIDATIVE STRESS REGULATE DJ-1 
SUMO2/3YLATION?  
LINKING DJ-1 AND SUMO2/3 TO A COMMON 
PATHWAY 
 
Treatments with drugs that mimic in vitro a neurochemical model of PD 
have been performed in human neuroblastoma cell lines. For the 
mitochondrial dysfunction and oxidative stress, hydrogen peroxide, DA, 
6-OHDA, were analyzed. For the proteosomal impairment, MG-132 was 
used. The global endogenous sumoylation and the DJ-1 expression were 
analyzed. 
 
5.1 Treatments of SH-SY5Y cells with Hydrogen 
Peroxide (H2O2 ) 
 
Confluent neuroblastoma cell lines have been treated with different 
increasing concentrations of hydrogen peroxide for 30 minutes. The initial 
goal was to follow the observation by others that oxidative stress induced 
SUMO-2/3 conjugation at high concentration of H2O2 (Manza et al., 2004; 
Saitoh and Hinchey, 2000; Zhou et al., 2004) in mammalian cell lines. Cells 
were lysed in Laemmly Buffer and whole protein extracts have been 
analyzed into a 6%-12% PAA gels. Western Blots were probed with 
antibody anti-SUMO-2/3 (Zymed), anti DJ-1 (home-made) and anti-Actin 
(Sigma). The protein analysis using a 6-12% PAA gel was necessary to 
observe both the high molecular masses conjugates to SUMO-2/3 and the 
free form of SUMO-2/3. Results shown in figure 36 are representative of 
three separate experiments. SH-SY5Y treated with H2O2 showed changes 
in the conjugation of SUMO-2/3. Global SUMO-2/3ylation was induced 
in SH-SY5Y treated with 100 mM H2O2 , while a decrease in their free form 
was showed.  
  94
Interestingly, lower concentration (1mM for 1 hr) induced a severe 
reduction in the level of SUMO-2/3 conjugation as demonstrated by 
Bossis and Melchior, 2006.  
These experiments indicated that different amount of hydrogen peroxide 
concentration affected SUMOylation differently. From the literature it’s 
now clear that low hydrogen peroxide concentration (1mM for 30 
minutes) prevents Ubc9-SUMO thioester formation and induces Uba2-
Ubc9 crosslink through a disulfide bond (Bossis and Melchior, 2006).  
 
Figure 36: SUMO-2/3 and DJ-1 expression analysis after treatments with different 
amount of hydrogen peroxide for 30 minutes or 1 hr. 
 
Global SUMOylation after oxidative stress treatments was also analyzed 
in immunofluorecence experiments using an anti SUMO-2/3 antibody. As 
for the western blot, confluent cells were treated with chosen amount of 
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H2O2 (0.1 mM and 100 mM for 30 minutes and 1mM for 1 hr). It was 
observed that when the SUMO-2/3ylation is inhibited or induced, the 
SUMO-2/3 proteins relocalized from the nucleus to the cytoplasm. Results 
are shown in figure 37 and are representative of at least three separate 
experiments. 
The physiological importance of this phenomenon is still under 
investigation.  
 
 
 
Figure 37: Immunofluorescence of SH-SY5Y untreated, treated with 100 mM H2O2 for 
30 minutes and 1mM H2O2 for 1 hr. Re-localization from the nucleus to the cytoplasm 
was detected for both treatments. Scale bar 45 μm. 
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Similar results were also obtained with COS-7 cell lines. Treating with 100 
mM hydrogen peroxide, SUMO-2/3ylation was massively induced (figure 
38A) and the endogenous proteins relocalized from the nucleus to the 
cytoplasm (figure 38B) in some limited group of cells. COS-7 were also 
transfected with HA-SUMO-2 and HA-SUMO-3 and treated with 
hydrogen peroxide: both proteins relocalize from nucleus to cytoplasm as 
indicated in figure 39. 
 
 
Fig 38A: Western blot SUMOylation analysis after hydrogen peroxide treatments on 
COS-7 at two different concentrations: 5 mM and 100 mM. Both treatments were 
carried out for 30 minutes. Results were compared to untreated cells.  
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Fig 38:B. Immunofluorescence with anti-SUMO-2/3 antibody of untreated COS-7 and 
treated with 100 mM H2O2 for 30 minutes. The nucleus/cytoplasm relocalization in a 
limited group of cells was detected. Scale bar 45μm. 
 
Fig 39A: Immunofluorescence with anti-HA of ectopic HA-SUMO-2 upon 100 mM 
H2O2 for 30 minutes. Scale bar 20 μm. 
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Fig 39B: Immunofluorescence with anti-HA of ectopic HA-SUMO-3 upon 100 mM 
H2O2 for 30 minutes. Scale bar 20 μm. 
 
5.2 Treatments of SH-SY5Y cells with the 
proteasome inhibitor MG-132 
 
SUMOylation was then analyzed after having treated confluent SH-SY5Y 
with 0.25, 0.5 μM, 5 μM MG 132, an inhibitor of proteosomal function, for 
both 1 hr and 24 hrs. Untreated cells and cells treated with the vehicle 
(DMSO) were considered controls. As shown in the figure 40A at 1 hr of 
treatments for each concentration, no changes in the SUMO-2/3 
conjugation were detected, while for treatments performed at 24 hrs a 
massive SUMO-2/3 conjugation inhibition was observed (figure 40B). For 
DJ-1 no expression change was detected at 1 hr, while at 24 hrs, DJ-1 
expression is decreased respect to the vehicle. Results shown in figure 40 
are representative of three independent experiments. 
  99
 
 
Figure 40) Treatments with different concentration of MG-132 at 1 hr (A) and 24 hr (B) 
on SH-SY5Y. Western blots were revealed for anti-SUMO-2/3 and anti-DJ-1 antibodies. 
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5.3 Treatments of SH-SY5Y cells with the HNE  
 
Confluent SH SY5Y cells were also treated with HNE, a drugs that induces 
lipid peroxidation. It was demonstrated that at 100μM for 30 minutes it 
was able to induce, as for treatments with 100 mM H2O2, a massive 
SUMO-3 conjugation (Manza et al., 2004). A titration experiment was 
performed and the data was confirmed. Treatments performed in our 
laboratory found an increase in the high molecular masses conjugates to 
SUMO-2/3 in a dose dependent manner (A.Chesi, personal 
communication). In these conditions DJ-1 showed a decreased expression 
in a dose dependent manner. The experiment was repeated in triplicates 
and figure 41 shows the representative result. 
 
 
Figure 41: DJ-1 expression analysis after increasing concentration of HNE treatments. 
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5.4 Treatments of SH-SY5Y cells with the MPP+ 
 
Confluent SH SY5Y has been treated with the Parkinsonian toxin MPP+ 
since previous results showed that SUMO-2/3 conjugation decreased in a 
dose dependent manner (A.Chesi, personal communication). In these 
conditions, DJ-1 showed an increase in protein expression. 
 
 
Fig 42: DJ-1 expression analysis after increasing concentration of MPP+ treatments. 
 
5.5 Treatments of SH-SY5Y cells with the 
Dopamine and 6-OHDA 
 
Confluent SH-SY5Y cells were treated with DA at different concentrations: 
10, 100, 250, 500 μM and 1mM for 24 hr; 500μM and 1mM for 1hr. Both 
SUMO-2/3 conjugation and DJ-1 expression were analyzed in western 
blot. Experiments were repeated in triplicates and representative results 
are shown in figure 43. DA didn’t affect the global SUMO-2/3 conjugation 
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since no differences were detectable respect to the untreated sample. 
Similar results were obtained treating SH-SY5Y cells with 6-OHDA (data 
not shown). Furthermore, immunofluorescence analysis didn’t display 
SUMO-2/3 relocalization detected after the hydrogen peroxide and the 
MPP+ treatments (figure 44).  
The level of DJ-1 was induced at 24 hr with 100, 250, 500 μM DA and at 1 
hr with 1 mM DA treatment. 
 
All immunofluorescence and western blot analyses are representative of at 
least three separate experiments. 
 
 
 
Fig 43: SUMO2/3 protein conjugation and DJ-1 expression analyses after treatments 
with DA. 
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Fig 44: Immunofluorescence with anti-SUMO-2/3 on SH-SY5Y treated with 10 and 500 
μM DA. Scale bar 45 μm. 
  104
6 IN VIVO CHARACTERIZATION OF SUMO-
2/3 POSITIVE CELLS  
 
6.1 Neuronal SUMO-2/3 expression analysis 
 
The expression of endogenous SUMO-2/3 protein was investigated in 
substantia nigra by immunofluorescence experiments. 
Mouse brain coronal slices were stained with anti-SUMO-2/3, anti-NeuN 
antibodies and nuclei were counterstained with DAPI. The anti-NeuN 
antibody recognizes a neuron-specific nuclear protein and reacts with 
mostly neuronal cell types with a primarily staining in the nucleus and a 
lighter staining in the cytoplasm. 
As shown in the figure 45, SUMO-2/3 expression was detected in neurons 
of the midbrain. As expected, other regions, such as hippocampus, were 
positive for SUMO-2/3 (figure 46). SUMO-2/3 protein showed a clear 
nuclear expression in all NeuN positive cells analyzed, in accordance to 
the cellular localization detected in mammalian cell lines. 
 
6.2 SUMO-2/3 expression analysis in substantia 
nigra dopaminergic cells 
 
SUMO-2/3 expression was analyzed in the dopaminergic neurons, using 
the specific labelling with the anti-TH antibody. SUMO-2/3 is expressed at 
in the nucleus of dopaminergic neurons. Results are shown in figure 47 
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Fig 45: Immunocytochemistry of midbrain sections with anti-NeuN and anti-SUMO-
2/3 antibodies. Nuclei were stained with DAPI. Scale bar 45 μm 
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Fig 46: Immunocytochemistry of hippocampal section with anti-SUMO-2/3 and anti-
NeuN antibodies. Nuclei were stained with DAPI. Scale bar 45 μm. 
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Fig 47: Immunocytochemistry of midbrain section with anti-SUMO-2/3 and anti-TH 
antibodies. Nuclei were stained with DAPI. Scale bar 45 μm 
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.  
Figure 48: Immunocytochemistry of midbrain sections labeled with anti-SUMO-2/3 
and anti-GFAP antibodies. Nuclei were stained with DAPI. Scale bar 45μm 
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6.3 SUMO-2/3  expression analysis in glial cells 
 
Since some positive SUMO-2/3 cells were NeuN negative, mouse brain 
coronal slides were stained with anti-GFAP antibody, a glial marker. 
Indeed SUMO-2/3 is present at the nuclear level also in astrocytes, as 
shown in figure 48. 
 
6.4 Downregulation of SUMO-2/3 expression upon 
MPTP treatments 
 
The expression of SUMO-2/3 was then investigated in mouse substantia 
nigra upon MPTP acute treatments. Mice received one injection of MPTP 
every two hours for a total of four doses over an 8 h period in one day. 
Slices were made 6 hrs and 12 hrs after the last injection.  
As shown in figure 49, in the substantia nigra of MPTP-treated mice SUMO 
2/3 was downregulated in its expression in all cells of the midbrain and 
not only in the dopaminergic neurons. This experiment was repeated five 
times.  Because the signal strength for SUMO-2/3 in substantia nigra 
MPTP-treated mice was lower than the staining in untreated conditions, 
slices were also analyzed by increasing the photomultiplier tube voltage 
on this channel, confirming the almost complete absence of staining.  
All images were collected with the same level of photomultiplier tube 
voltage in 594 channel. Results shown in figure 49 are representative of 
five independent and separate experiments. 
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Figure 49: Immunocytochemistry of midbrain sections labelled with anti-TH and anti-
SUMO-2/3. Substantia Nigra was isolated from untreated mice and treated with MPTP 
after 6 and 12 hours the last injection. Scale bar 45 μm. 
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 DISCUSSION 
 
Parkinson’s Disease (PD) is the second most common neurodegenerative 
disorder after Alzheimer Disease (AD). The etiology of the majority of PD 
cases is still unknown, but it is likely to be a combination of both genetic 
and environmental factors. The recent identification of genetic loci and 
genes linked to familiar PD have consistently advanced the knowledge on 
the molecular mechanisms involved in the pathogenesis.  
Recently it has been found that mutations in DJ-1 are the second cause of 
EOARPD after Parkin (Bonifati et al., 2003). A neuroprotective role of DJ-1 
has been proposed but its exact function is still unknown.  
 
To study the molecular mechanism of DJ-1-mediated protection against 
the nigrostriatal degeneration, an Yeast Two Hybrid Screening has been 
performed in the laboratory of Prof. S. Gustincich. 
The prey consisted of components of an yeast expression library 
synthesized from cDNAs of the human foetal brain. In the screening, 
eleven different interactors have been identified and confirmed in yeast. 
One of these clones encoded DJ-1 itself, a finding that proved the validity 
of the screening and consistent with reports that DJ-1 may act as a 
homodimer. 
Among all the DJ-1 interactors, this thesis focused on the DJ-1 
modification by SUMO, since Small Ubiquitin Modifiers 1 (SUMO-1), 
SUMO-activating enzyme Uba2 and SUMO conjugating enzyme Ubc9 
were fished out. 
While we were investigating the potential DJ-1 modification by SUMO-1, 
Shinbo et al. reported that DJ-1 is sumoylated by SUMO-1 at Lys 130, 
while Junn et al. reported that SUMO-1, Uba2 and Ubc9 are interactors of 
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DJ-1 in YIIH using a human adult brain cDNA library. These findings 
validated the quality and the specificity of the screening method.  
We first tried to detect SUMO-1ylated DJ-1, however our efforts were 
unsuccessful (data not shown). 
Since HEK293T is commonly used to analyze SUMO conjugation, all our 
experiments were carried out in this cell line. To detect DJ-1 modification 
by SUMO-1, experiments were repeated in similar conditions to those 
published, but the post translational modification of DJ-1 was never 
detectable. Shinbo et al. examined the DJ-1 SUMO-1ylation in human 
H1299 (human lung cancer cell line) and they detected SUMOylation on 
both endogenous DJ-1 and with ectopic Flag-DJ-1 co-transfected with T7-
SUMO-1 and Ubc-9-HA. Furthermore, the same author reported that HA-
PIASxα and HA-PIASγ bind DJ-1 and they function as E3-SUMO-1 ligases 
(Takahashi et al., 2001).  
Since a different cell line was used in the paper of Shinbo et al., we may 
suggest that a different cell background could alter the effects of ectopic 
protein expression and the consequent detection of the post translational 
modification. Furthermore, GFP-SUMO-1 was transfected instead of a T7-
SUMO-1. GFP-SUMO-1 can modify different substrates as demonstrated 
for GATA-1 (Collavin et al., 2003) and p53 (Gostissa et al., 1999) but in the 
case of DJ-1 a steric hindrance may occur.  
 
This thesis demonstrated that DJ-1 is modified in vitro and in vivo by 
SUMO-2/3. Interestingly these two proteins were not isolated from the 
YIIH screening: probably they are not present in the library or they are 
weakly expressed. No experiments have been done to validate these 
hypotheses. 
The YIIH found Uba2 and Ubc9 as DJ-1 protein interactors. It is important 
to note that Ubc9 doesn’t discriminate between SUMO-1, SUMO-2 and 
SUMO-3 (Tatham et al., 2001) and that it is the only E2-conjugating 
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enzyme known in vertebrates. Several papers investigated protein 
SUMOylation after having fished out enzymes belonging to the SUMO 
conjugation pathway, as Ubc9 or PIAS (Giorgino et al., 2000; Pan et al., 
2006; Martin et al., 2007) 
We confirmed that DJ-1 interacted with ectopic HA-Ubc9 in vitro, opening 
the intriguing hypothesis that DJ-1 could be modified by SUMO moieties 
different from SUMO-1. 
Unfortunately, it is still not known the subcellular compartment in which 
DJ-1/HA-Ubc9 interaction takes place. Cellular fractionation and 
immunoprecipitation are necessary to explore this aspect. The DJ-1/Ubc9 
interaction may have also a biological function independent on the E2-
conjugating activity, as demonstrated for the transcriptional factor SOX-4 
(Pan et al., 2006) and for the GLT4, GLT1 glucose transporter (Giorgino et 
al., 2000). 
This study demonstrated that DJ-1 is modified by SUMO 2/3 in vitro. The 
post translational modification was detected both on endogenous proteins 
and overexpressing the SUMOylation pathway and DJ-1 in HEK293T. 
The SUMO-2/3 ylation of DJ-1 was further shown in vivo in adult mice 
substantia nigra and in striatum, the two brain regions involved in the PD 
dopaminergic nigrostriatal degeneration.  
It will be interesting analyzing this modification in other brain regions and 
in different tissues. The DJ-1 SUMOylation may exert a tissue-specific 
biological function. 
To detect endogenous DJ-1-SUMO-2/3 modification, 
immunoprecipitation experiments were essential, but different technical 
difficulties have been met. First of all, the amount of modified DJ-1 was 
very low; this aspect could be due to at least two different reasons. First, 
the Sulfhydryl alkylating agent inhibitor N-ethylmaleimide (NEM) is not 
specific for blocking the process of desumoylation, since it covalently 
modifies Cys residues in proteins, irreversibly inhibiting the formation of 
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Cys linkage. Second, the amount of DJ-1 that is modified in a specific 
moment could be very low, similarly to the majority of the sumoylated 
proteins identified in vivo.  
A great improvement in the detection of the DJ-1 modification was 
obtained after the affinity purification of the anti-DJ-1 antibody. The 
home-made anti-DJ-1 antibody enriched the amount of 
immunoprecipitated DJ-1 respect to the commercial available ones, 
allowing the detection of modified DJ-1 fraction. To further validate the 
endogenous DJ-1 modification by SUMO-2/3, a proteomic approach was 
specifically designed.  
The proteomic approach is generally used to overcome the difficulty of 
identifying low-abundant sumoylated proteins. Cell lines stable 
transfected with tagged SUMO are characterized by a dramatic higher 
sumoylated protein levels than that of untransfected cells (Table 2) (Li et 
al., 2004; Rosas-Acosta et al., 2005, Vertegaal et al., 2006). Cell lysates are 
then used for immunoprecipitation or affinity chromatography 
purification and the isolated sumoylated proteins are trypsinized and 
identified by Mass Spectrometry (MS). 
In this thesis we used the bidimensional electrophoresis to confirm that 
endogenous DJ-1 is modified by SUMO2/3 in vitro. Furthermore, we have 
tried to confirm it using Mass Spectrometry. Experiments were designed 
in the following way: several immunoprecipitations were loaded together 
using anti-DJ-1 antibody and anti-IgG as control. Two SDS-PAGE were 
processed separately. The first was subjected to Blue Coomassie and Silver 
Staining and the second was blotted and revealed with anti-DJ-1 antibody. 
This last one was used as positive control of immunoprecipitated DJ-1, 
using the enhanced chemiluminescence system. This gel was further used 
as reference for the first one: the region in which the slower migrating 
band was detected would be cut and subjected to trypsinization. The main 
problem of this approach was that no differentially-immunoprecipitated 
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bands using the anti-DJ-1 antibody was detected with Blu Coomasie and 
Silver Staining respect to that performed with anti-IgG. These results 
indicated that the amount of endogenous DJ-1 modification was too low to 
be compatible to a proteomic approach such as Mass Spectrometry. 
To confirm DJ-1 SUMO-2/3ylation, we resorted to Isoelectrofocusing 
(IEF). Since the amount of modified DJ-1 is low, we were obliged to 
overload the strips with 1mg of proteins. Although the overloading 
explained the weak focalization of DJ-1 itself, it allowed the detection of 
SUMO-2/3-DJ-1. The perfect matching between the spot of modified DJ-1 
and that one recognized by anti-SUMO-2/3 removed any possible doubts 
about endogenous DJ-1 SUMO-2/3ylation in HEK293T and confirmed the 
results previously obtained by Immunoprecipitation. 
It is worth noting that preliminary experiments in which 300 μg of total 
cell lisates were subjected to IEF demonstrated a perfect focalization as 
previously shown (Taira et al., 2004; Choi et al., 2006) but didn’t allow the 
detection of modified DJ-1 (data not shown). 
In a second approach, largely used in literature, we analyzed DJ-1 
sumoylation after overexpressing SUMO-2/3, Ubc9 and DJ-1 itself. A first 
analysis was focused on the characterization of the SUMO-2 and SUMO-3 
conjugation pathways. 
The conflicting designation of SUMO-2 and SUMO-3 in number of 
publications has led to confusion on nomenclature. This work used the 
original notation described in the National Center for Biotechnology 
Information database: (The SUMO-2 and SUMO-3 accession number are 
respectively AAIO7854 and AAHO8420.1) 
To improve SUMO 2/3 conjugation, the co-transfection of Ubc9 was 
essential, while the transfection of wild type SUMO-2 or SUMO-3 alone 
induced a weak conjugation. Two forms of SUMO-3 were detected: the 
slower migrating form is the unactivated protein, the other is the activated 
one that has been subjected to the cleavage of the C-terminal. Since the 
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activation of SUMO-2 released only 2 amino acids, these two forms could 
not be detected. Using the strategy of PCR Site-Directed Mutagenesis the 
unconjugable forms of SUMO-2 and SUMO-3 have been created: the C-
terminal di-Gly motif has been converted into a di-Ala motif and this 
mutation abrogated the possibility of ectopic SUMO-2 and SUMO-3 
activation and conjugation to endogenous or overexpressed substrates. 
Truncating forms of SUMO, lacking the C-terminal Gly required for 
attachment to substrates (SUMO1/2/3Δ6), were also used. 
The SUMO-2 and SUMO-3 protein localization was further analyzed. 
SUMO-2 in the conjugable form displayed mostly a nuclear and a nuclear 
bodies localization while the unconjugable forms partially relocalized in 
the cytoplasm. As reported for SUMO-1, SUMO-2 conjugation may also be 
involved in transcriptional regulation or in protein nuclear import.  
Wild type SUMO-3 displayed an increased cytoplasmic localization 
respect to wild type SUMO-2. This indicated the possibility that SUMO-3 
could modify different targets respect to SUMO-2, according to a different 
subcellular localization. Furthermore, since these two proteins share 95% 
of homology, they could modify the same targets but under different 
cellular events, leading to a different biological function. The different 
subcellular localization of SUMO-2 and SUMO-3 was according to that 
one reported by Su. et al., 2002. 
This work confirmed that DJ-1 could be conjugated to the SUMO family 
members, SUMO-2 and SUMO-3, in ectopic expression. The co-
transfection of the E2-conjugating enzyme Ubc9 was essential to detect the 
DJ-1 modification. This result indicated that the amount of DJ-1 that is 
modified in physiological conditions is very low. Furthermore, it is still an 
open question whether this modification can be stabilized or induced 
upon specific cellular conditions, such as oxidative stress. In our 
experimental conditions DJ-1 was modified by both SUMO-2 and SUMO-
3.  
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Since the efficiency of SUMO-3 conjugation was higher than that of 
SUMO-2, we carried out experiments on SUMO-3 overexpression. 
A big challenge of this thesis was the identification of the Lys responsible 
of DJ-1 modification. Sumoylation of proteins has been shown to occur at 
specific Lys residues, which are in most cases embedded in a consensus 
sequence (I/L/V)KXE, where X represents any amino acid. 
Several proteome-scale analyses have been performed to delineate the 
potential sumoylated substrates, but the exact sumoylation sites still 
remain to be identified. Only a small fraction of the substrates, often less 
that 1%, is sumoylated in vivo at any given time (Johnson, 2004). Therefore 
in silico identification of SUMO substrates with their respective sites are 
fundamental for understanding the mechanism of sumoylation-related 
regulations in eukaryotic cells and suggesting potential candidates for 
further drug design. 
In this work in silico programs were insufficient to predict the sumoylation 
consensus sequence, most probably because they are designed for SUMO-
1 conjugation: the pathway of SUMO-2/3 activation and conjugation and 
their substrates have still to be analyzed and compared to those modified 
by SUMO-1. 
Very few substrates have been till now identified as targets for SUMO-2/3 
modification in vivo: p53 (Li et al., 2006), PML (Fu et al., 2005), c-Myb, 
(Sramko et al., 2006) Topoisomerase II (Azuma et al., 2005), C/EBPβ (Eaton 
at al., 2003), Tau and α-synuclein. (Dorval et al., 2006) All these substrates 
are also modified by SUMO-1.  
Several questions are still open on the specificity of the sumoylation site. 
1) Are the Lys responsible for SUMO 1 conjugation the same as for SUMO 
2/3? 2) Which is the molecular mechanism that allow SUMO-2/3 
modification of a specific substrate respect to SUMO-1?  
It is known that in p53, SUMO-2/3 and SUMO-1 share the same 
conjugating site at Lys 386, and the same occurs for C/EBPβ in which the 
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major site of conjugation of SUMO-2/3 as well for SUMO-1 is Lys 173. 
Similar interplay occurs for c-Myb. In contrast, PML has three mayor 
sentrinization sites for SUMO -1: Lys 65, Lys 160 and Lys 490, while 
SUMO-3 is conjugated to Lys 160 and is essential for a stable nuclear 
localization of PML.  
SUMO-1 is the most studied Ubiquitin like Modifier, but for some 
substrates the identification of Lys responsible of SUMOylation was very 
challenging. PCNA has 18 Lys residues which were individually changed 
to Arg. Only the combination K127/164R specifically altered the pattern of 
SUMO conjugates. It is worth noting that Lys 127 lies within a postulated 
SUMO-modification site, while Lys 164 is a non-consensus SUMO 
conjugation site, but is highly conserved from yeast to human (Hoege et 
al., 2002).  
Daxx was initially indicated to be sumoylated at Lys 630 and Lys 631 by 
Jang et al., 2002, while a more recent paper indicated that 15 Lys have to be 
mutated together in order to completly abolish SUMOylation (Lin et al., 
2006). The authors argued as possible discrepancy the different cell line 
used in these works, but they didn’t indicated the criteria by which they 
mutated specific Lysines. The Glucocorticoid (GC) receptor has also two 
major modification sites, Lys 277 and Lys 293, but faint bands were still 
visible suggesting that some sumoylation may occur on other Lys than 
those conforming to the consensus sequence ψKXE (Tian et al., 2002).  
It may be concluded that although in the majority of cases SUMOylation 
can occour on consensus motif predicted by in silico program, both false 
positives and false negatives may occur. Molecular mechanisms that 
regulate activation and conjugation have to be analyzed to solve these 
issues.  
In the case of DJ-1, Lysines responsible of SUMO-3 conjugation are still 
unknown. Unlike other substrates, SUMO-3ylation occurs on different Lys 
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respect to SUMO-1 and since no single mutant abrogated the SUMO-
3ylation, more than one Lys can be sumoylated alternatively.  
A provocative hypothesis is that ectopic DJ-1 could be modified 
differently than the endogenous protein. Since all experiments are done 
overexpressing also SUMO-3 and Ubc9, the cell could lose the specificity 
of the modification in a satured cellular environment for SUMOylation. 
Alternatively, SUMO may have a random access on sumoylation sites 
normally hidden by the proper protein folding.  
 
Further experiments are necessary to investigate the biological function of 
the hypersumoylated pathological mutant DJ-1 Leu166Pro (DJ-1 L166P). 
The hypersumoylation could be due to a multisumoylation on different 
Lys or to a di-SUMO chain modification on a single Lys 
(multisumoylation). 
We may hypothesize that Sumoylation probably may occurs on 
monomeric DJ-1 L166P, since it is known that this mutant protein cannot 
form dimers. Furthermore, sumoylation could compete with 
Ubiquitination inhibiting the degradation of DJ-1 L166P by UPS. The 
SUMO-2/3-DJ-1 L166P may further accumulate into High Molecular 
Weight Complexes with the consequent protein sequestration important 
for cell survival. This hypothesis suggests that the pathological mutation 
DJ-1 L166P may lead to an unexpected gain of function.  
A similar improper SUMOylation of DJ-1 L166P was observed by Shinbo 
et al. A ladder of bands was detected indicating multi or poly SUMO-1 
conjugation. Since SUMO-1 cannot form poly SUMO-chain, it is most 
probable that the misfolded DJ-1-L166P could expose multiple Lys residue 
further resulting in multisumoylation.  
 
To understand the biological function of DJ-1 SUMO 2/3ylation, 
biochemical analyses have to be carried out. Controversial results have 
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reported that DJ-1 works as a protease (Olzmann et al., 2004), or as a 
chaperone (Shendelmann et al., 2004; Zhou et al., 2006). DJ-1 has three Cys 
at amino acid number 46, 53, 106 and it has been reported that oxidation of 
Cys 106 is essential to exert its full activities (Takahashi et al., 2004; Zhou et 
al., 2006). Abnormal oxidation of DJ-1 has been found in patients with PD 
and in patients with AD (Bandopadhyay et al., 2004; Choi et al., 2006) and 
these findings indicated that the oxidation status of DJ-1 modulates its 
function.  
In this thesis, it has been demonstrated that functional mutants DJ-1 
Cys53Ala and DJ-1 Cys106Ala were sumoylated as the wild type protein. 
It will be interesting analyzing the SUMOylation of these functional 
mutants upon oxidative stress conditions. Most importantly, it will be 
crucial assessing whether this modification could alter DJ-1 biological and 
biochemical activity.  
Since DJ-1 and SUMO-2/3 are oxidative stress sensor proteins, an 
intriguing hypothesis is that oxidative stress conditions could regulate DJ-
1 modification. This thesis has demonstrated that different treatments can 
induce or inhibit the global SUMO 2/3 conjugation, confirming previous 
results (Saitoh et al., 2000; Manza et al., 2004; Bossis et al., 2006). 
Isoelectrofocusing may be used to analyze the endogenous SUMO 2/3 DJ-
1 modification. Furthermore, with this approach, the DJ-1 pI shift upon 
stress condition would be a positive control (Taira et al., 2004; Choi et al., 
2006). To understand better the biochemical conjugation pathway, the 
amount of free radicals produced by each treatments could be measured 
with 2’,7’-Dichlorofluorescein Diacetate (DCFH-DA) assay. The induction 
or the inhibition of the SUMO-2/3 conjugation pathway is probably 
regulated by the intracellular level of hydrogen peroxide.  
An alternative approach may take advantage of the transient transfection: 
ectopic expression of DJ-1 could be analyzed after different treatments, 
and compared to SUMO-3 conjugable or unconjugable overexpression. 
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This experiment may indicate whether upon conditions in which global 
SUMO-2/3ylation is induced or inhibited, DJ-1 SUMOylation is affected. 
In this thesis some preliminary results indicated that, in ectopic 
overexpression of 2X-Flag-DJ-1, HA-SUMO-3 and HA-Ubc9 and upon 
oxidative stress, DJ-1 is hypersumoylated since a ladder of bands were 
specifically detected with the anti-Flag antibody (data not shown). This 
result has to be confirmed. Experiments on tagged DJ-1 stable cell lines 
transfected with the SUMO-3 conjugation machinery and subjected to 
oxidative stress conditions may also be performed.  
 
In this thesis SUMO-2/3 was also investigated by immunofluorescence in 
Substantia Nigra isolated from acute MPTP-treated mice. A 
downregulation of the signal was detected respect to the nuclear 
localization in untreated mice. Interestingly, the downregulation of 
SUMO-2/3 detection was not limited to dopaminergic neurons, since 
MPTP is specifically internalized into them, but also to other cell types. 
Further investigations are necessary to elucidate this phenomenon. 
SUMO-2/3 may also aggregate in HMW complexes inhibiting the 
detection in brain tissue. To explore this possibility, experiments have to 
be supported by Western blot analysis. A crucial experiment will be the 
demonstration that global sumoylation could be affected by a Parkinson 
disease-like treatment, such as MPTP, and that DJ-1 SUMO-2/3lation 
could be affected as well with a consequent alteration of its physiological 
activity. 
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